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The pancreatic islet b cell senses circulating levels of calorigenic nutrients to secrete insulin according to the
needs of the organism. Altered insulin secretion is linked to various disorders such as diabetes, hypoglyce-
mic states, and cardiometabolic diseases. Fuel stimuli, including glucose, free fatty acids, and amino acids,
promote insulin granule exocytosis primarily via their metabolism in b cells and the production of key
signaling metabolites. This paper reviews our current knowledge of the pathways involved in both positive
and negative metabolic signaling for insulin secretion and assesses the role of established and candidate
metabolic coupling factors, keeping recent developments in focus.Introduction
Glucose homeostasis in the physiology and in pathology of
diabetes and hypoglycemic states is largely determined by insu-
lin-producing b cells and glucagon-producing a cells of the islets
of Langerhans on one side and by the action of these two hor-
mones on their respective receptors in liver, muscle, and adipose
tissue on the other side (Nolan et al., 2011). The pancreatic b
cells serve as a glucostat in the homeostatic feedback system
and operate with a 5 mM glucose threshold, resulting in con-
centration-dependent insulin secretion covering the range of
5–20 mM glucose, with the steepest slope of the sigmoidal
dose-response curve seen at physiological levels of 5–8 mM.
b cells also respond to other nutrients (amino acids, fatty acids,
and ketone bodies); they respond very sensitively to neurohor-
monal stimulation (acetylcholine, glucagon-like peptide-1,
glucagon, and others) but in an absolutely glucose-dependent
manner. The basal insulin secretion that occurs at blood nutrient
levels observable between meals contributes as much as half of
the total daily insulin delivery (Meglasson and Matschinsky,
1986). These physiological functions of the general fuelstat are
profoundly impaired in diabetic and hypoglycemic states. Inten-
sive research efforts in the last several decades have been
devoted to working to elucidate the underlying biochemical
and biophysical processes involved in fuel-induced insulin
secretion (FIIS). In the context of the stimulation of insulin secre-
tion, we define fuels asmolecules that are calorigenic and whose
metabolism yields necessary signals to promote insulin secre-
tion. A critical appraisal of the current state of knowledge of
this topic appears to be timely and is provided in this review.
It is generally accepted that glucose-induced insulin secretion
(GIIS) requires that this sugar be metabolized and that the
coupling of its metabolism to secretion involve a variety of critical
intermediates and cofactors, termed metabolic coupling factors
(MCFs) (Figure 1) (Malaisse, 1983; Matschinsky et al., 1986b;
Prentki, 1996). In a nutshell, fuel metabolism provides regulatory
MCFs (e.g., citrate, malonyl-coenzyme A (CoA), glutamate,162 Cell Metabolism 18, August 6, 2013 ª2013 Elsevier Inc.adenine nucleotides), which modulate metabolic networks
involved in FIIS, and the effectory MCFs (ATP, cyclic AMP
[cAMP], nicotinamide adenine dinucleotide phosphate [NADPH],
reactive oxygen species [ROS]) that are directly involved in the
triggering and amplification arms of FIIS (see also Table 1) by
influencing the activity of late effectors (K+ATP/SUR1 channel,
Ca2+ channels, exocytosis-facilitating soluble NSF attachment
protein receptor [SNARE] proteins). Overall regulation of FIIS at
the b cell level is achieved by a balance between the pathways
that produce the MCFs and by negative modulators (enzymes
and pathways that interfere with the production of the MCFs)
and by signal removers (the enzymes and pathways that
degrade the MCFs) (Figure 1).
Glucose metabolism in b cells has unique features: glucose
activation of metabolism is governed by substrate availability
(a push rather than pull mechanism), which is not operative in
most other tissueswheremetabolismprimarily responds tonerve
and hormonal stimulation, and energy expenditures of the tissue
workload (Matschinsky, 1996). This is possible because (1)
glucose transport into b cells is not limiting, which results in rapid
equalization of extra- and intracellular glucose by transporters
Glut-1 in human or Glut-2 in rodents (De Vos et al., 1995; Thorens
and Mueckler, 2010), and (2) glycolysis is controlled by glu-
cokinase, a hexokinase isoenzyme with low glucose affinity
(substrate concentration at which half-maximal enzyme activity
is seen [S0.5] of about 8 mM), sigmoidal glucose dependency
(Hill coefficient of 1.7), and lacking any form of feedback control
(Meglasson and Matschinsky, 1984). The isoforms of hexoki-
nases with low KM for glucose are repressed in primary b cells
(Schuit et al., 1999, 2012). Since the use of glucose-6-phosphate
by other pathways (e.g., glycogen synthesis and pentose-
phosphate shunt) is very limited in a b cell (Schuit et al., 1997),
glucose usage is primarily determined by glycolysis and the
cellular levels of glucokinase and glucose (Matschinsky, 1996).
Glucose stimulation of b cells is achieved by a tight link
between glycolysis and mitochondrial metabolism for the
Figure 1. Metabolic Signaling of Insulin Secretion at a Glance
Nutrient secretagogues, glucose, free fatty acids (FFAs), and amino acids (aa)
are metabolized in the b cell when their intracellular concentrations reach
certain threshold levels to provide regulatory metabolic coupling factors
(R-MCFs) and effectory MCFs (E-MCFs). The R-MCFs (e.g., citrate, NADH/
NAD+, malonyl-CoA, GTP, long-chain acyl-CoA compounds [FA-CoA],
glutamate, adenine nucleotides) either directly (because they are metabolic
precursors) or indirectly (because of allosteric effects) enhance the production
of E-MCFs (ATP, cAMP, monoacylglycerol [MAG], NADPH, ROS, inositol
1,4,5-trisphosphate (InsP3), short-chain acyl-CoA compounds [SC-acyl-
CoA]), which have a direct impact on insulin granule exocytosis. E-MCFs
activate late effector components of the exocytosis machinery, including
K+ATP channel/SUR1/Ca
2+, SNAREs, Munc13-1, cytoskeletal proteins, etc.,
thereby triggering the release of insulin. In order to prevent excessive secretion
of insulin, b cells are also equipped with brake mechanisms that control
excessive production of R-MCFs and E-MCFs. These mechanisms include
metabolic pathways that act as negative modulators (AMPK, carnitine
palmitoyltransferase I [CPT-I], glucose-6-phosphatase [G6Pase], short-chain
3-hydroxyacyl-CoA dehydrogenase [HADHSC], cytosolic isocitrate dehydro-
genase isozyme 1 [IDH1], and uncoupling protein 2 [UCP2]), which lower the
generation of R-MCFs, and signal removers (a/b-hydrolase domain 6 [ABHD6]
for MAG hydrolysis, various ATPases, phosphodiesterases for cAMP break-
down, ROS scavengers, and various NADPH oxidizing enzymes), which
control the levels of E-MCFs.
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by low levels of lactate dehydrogenase (LDH) (Malmgren et al.,
2009; Schuit et al., 1997; Sekine et al., 1994). During maturation
of b cells, several genes, including hexokinase-1, LDH, and
monocarboxylate transporter (MCT), that are metabolically inap-
propriate for insulin secretion are repressed, ascertaining that
effective stimulus-secretion coupling is in place (Pullen et al.,
2010; Pullen and Rutter, 2013; Schuit et al., 2012; Thorrez
et al., 2011). Thus, low LDH and MCT ensure that pyruvate and
lactate, derived frommuscle during exercise, do not cause hypo-
glycemia by stimulating insulin release inappropriately (Ainscow
et al., 2000; Ishihara et al., 1999; Otonkoski et al., 2007). It should
be mentioned that transgenic mice with b cell-specific overex-
pression of MCT-1 do not show altered GIIS but respond to ex-
ercise and pyruvate with elevated secretion (Pullen et al., 2012).Therefore, glucose carbons are largely converted to pyruvate,
which is primarily used in the citric acid cycle, resulting in
enhanced oxidative phosphorylation (Schuit et al., 1997). Thus,
for GIIS, the rate of glucose phosphorylation determines the
rate of glycolytic and oxidative ATP production and the phos-
phorylation potential (ATP/ADP 3 Pi) (Doliba et al., 2012). ATP
and MgADP serve as essential MCFs controlling the plasma
membrane potential and triggering insulin release when the
membrane is depolarized (Henquin, 2009). Essential partners in
this triggering process operating in tandem are the nucleotide-
sensitive KATP/SUR1 channel complex (regulated by ATP and
MgADP) (Figure 2) and the voltage-sensitive L-type Ca2+ channel
(MacDonald et al., 2005b; Proks et al., 2010).
There is, however, compelling evidence that the classical ATP/
KATP/Ca
2+ signaling pathway is complemented by amplification
processes mediated by additional MCFs and activation of
diverse auxiliary metabolic pathways (some of them cyclical)
as summarized in Figure 2 (Aizawa et al., 1998; Henquin, 2009;
Prentki, 1996). Many of these auxiliary mechanisms are not fully
established or remain hypothetical and are therefore the target
topic of this article.
In this review, we discuss the regulation of insulin secretion by
fuel stimuli, keeping the recent developments in metabolic
signaling in focus. The relevant metabolic pathways and their
roles in the control of nutrient-stimulated insulin secretion will
be reviewed as we build a global picture and model of the
biochemical basis of insulin secretion promoted by glucose,
amino acids, and fatty acids.
Metabolic Signaling in Biphasic Insulin Secretion
The release of insulin induced by a step increase in glucose con-
centration from a low basal value (z3 mM) to 10–20 mM is
biphasic both in vitro and in vivo (Henquin et al., 2006b). An initial
rapid, transient, 3–10 min peak is followed by a slowly devel-
oping second phase of release, as shown in classical studies
with the isolated perfused rat pancreas (Curry et al., 1968). A
feature of prediabetes is that first-phase secretion is reduced,
whereas in type 2 diabetes (T2D) the first phase is almost abol-
ished and second-phase secretion is reduced following a bolus
of glucose injection (Cheng et al., 2013; Porte and Kahn, 2001).
This biphasic pattern does not exist in vivo under physiological
conditions in which blood glucose rises relatively slowly after a
meal. However, experimental biphasicity is a useful phenome-
non for understanding the biochemical basis of FIIS and for iden-
tifying prediabetes in humans.
Determining how granule pools are linked to phasic secretion
is an active field of research (Fridlyand and Philipson, 2011;
Takahashi et al., 2010; Wang and Thurmond, 2009). The current
model proposes that first-phase insulin secretion results from a
readily releasable pool of granules docked to the plasma mem-
brane (old faces), whereas the second phase results from a
reserve pool of granules located further away (resting new-
comers) that are recruited upon stimulation, docked, and then
fuse with the plasma membrane. This has been challenged in a
new model, based on the results from total internal reflection
fluorescence (TIRF) microscopy, which proposes that both
phases consist of granules that are recruited upon stimulation
and immediately fused to the plasma membrane (restless new-
comers) (Seino et al., 2011). As the ability of TIRF microscopyCell Metabolism 18, August 6, 2013 ª2013 Elsevier Inc. 163
Table 1. Candidate Metabolic Coupling Factors in Fuel-Induced Insulin Secretion
Metabolite R-MCF E-MCF Targets and Substrates Possible Roles
Citrate O NA ACL, ACC, M-PFK Pyruvate cycling, metabolic oscillations
NADH/NAD+ O NA many enzymes, ETC ATP production, redox control
Malonyl-CoA O NA CPT-I, FAS, malonylation? crosstalk glucose and lipid metabolism
Fatty acyl-CoA O + many enzymes, KATP, acylation? GL/FFA cycling, exocytosis, Ca
2+
Glutamate O + GDH, ACC, Glu receptor? crosstalk glucose, aa, and FA metabolism
GTP O + GDH, small G proteins and exocytosis? crosstalk glucose and aa metabolism
ATP/ADP/Pi O NA many enzymes, carriers energy metabolism
AMP/ATP, ADP/ATP ++ NA AMPK negative modulation of secretion
ATP NA +++ KATP Ca
2+ signaling
MgADP NA +++ SUR1 Ca2+ signaling
cAMP NA ++ PKA, Epac2 Ca2+ channels, exocytosis proteins
NADPH/NADP+ NA ++ glutaredoxin, Kv exocytosis redox control, Ca2+
InsP3 NA ++ InsP3 receptor intracellular Ca2+ mobilization
ROS NA + exocytosis proteins? exocytosis complex redox control
Short-chain-CoA NA + effector acylation? exocytosis complex control
FFA NA + GPR40, Ca2+ channels? exocytosis, Ca2+ signaling
Diacylglycerol NA + PKC, PKD, Munc13-1 exocytosis, channels
Monoacylglycerol NA + Munc13-1, PKC? exocytosis, channels
R-MCF, regulatory metabolic coupling factor; E-MCF, effectory metabolic coupling factor; O, established; +++, consensus; ++, strong evidence; +, to
be confirmed or debated; ‘‘?’’ refers to only the one hypothesized target or substrate just preceding the question mark. The E-MCF listed in the lower
half of the table may also function as allosteric regulatory factors in numerous steps of intermediary metabolism that influence the coupling mecha-
nisms of fuel-induced insulin secretion. Thus, the distinction between two categories (R-MCF and E-MCF) is not absolute. InsP3, inositol 1,4,5-triphos-
phate; FFA, free fatty acid; ROS, reactive oxygen species; short-chain-CoA, short-chain acyl-CoA compounds; ACL, ATP-citrate lyase; ACC,
acetyl-CoA carboxylase; M-PFK, muscle-type phosphofructokinase; ETC, electron transport chain; CPT-I, carnitine palmitoyltransferase I; FAS, fatty
acid synthase; GDH, glutamate dehydrogenase; AMPK, AMP-activated protein kinase; KATP, Kir6.2, inwardly rectifying potassium channel subunit;
SUR1, regulatory subunit of the KATP channel and the target of sulfonylureas; PKA, protein kinase A; Epac2, exchange proteins directly activated
by cAMP; Kv, repolarizing voltage-dependent potassium channel; PKC, protein kinase C; PKD, protein kinase D; GL, glycerolipid; aa, amino acid;
FA, fatty acid. Some MCFs shown in the table (cAMP, InsP3, diacylglycerol) are classical second messenger molecules. NA, not applicable.
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newcomer granules represent only those very close to the
plasma membrane and not necessarily the granules slightly
away from the membrane that also contribute to both phases
of secretion.
Until recently, it was thought that first-phase insulin secretion
occurs following KATP channel closure and a rise in cytosolic
Ca2+, whereas second phase was due to a number of amplifica-
tion mechanisms synergizing with Ca2+ elevations (Newsholme
and Krause, 2012; Prentki, 1996). A study by Henquin (2009)
showed that the Ca2+ triggering pathway is essential, but not
very efficient, if glucose does not activate the amplification
pathway(s) that augment the action of the triggering Ca2+ on
exocytosis (Figures 1 and 2). Previous inappropriate terminology
referring to the triggering and amplification pathways as the
KATP-dependent and -independent pathways has been aban-
doned, and reasons for that have been reviewed (Henquin,
2009). Are there clear boundaries between triggering and ampli-
fication pathways with respect to biphasic insulin secretion? The
recent view is that there are few, if any, as based on examination
of Ca2+ oscillations in mouse islets together with parallel deter-
minations of insulin secretion oscillations (Henquin, 2009).
Glucose has been shown to have little influence on the amplitude
of Ca2+ oscillations but does control the time lag of the triggering
signal. In addition, the modulation of insulin secretion pulses by164 Cell Metabolism 18, August 6, 2013 ª2013 Elsevier Inc.glucose largely depends on the amplifying pathways. Quantita-
tive estimates indicate that the Ca2+ and amplification signals
account for both phases of secretion equally. Thus, there are
more similarities than differences between the two phases of
GIIS in terms of signaling, and the current evidence indicates
that second-phase secretion results from iterations of the first
phase. In terms of metabolic signaling, the most recent model
on the nature of granule pools (restless newcomers granule
model) (Seino et al., 2011) fits with the novel view that second-
phase secretion consists of iterations of the first phase (Henquin,
2009).
The Uphill Struggle to Understand b Cell Metabolic
Signaling
Great strides have been made during the past decades
regarding the biochemical mechanisms that operate in
nutrient-induced stimulus-secretion coupling (Maechler et al.,
2010; Newsholme and Krause, 2012; Nolan and Prentki, 2008).
One may therefore wonder why such intensive research efforts
have provided relatively little true understanding of themetabolic
basis of GIIS. The problem possibly lies in the fact that it is diffi-
cult to demonstrate something unequivocally in this field with
relatively straightforward approaches (like the knockdown of
an enzyme) without causing unwanted alterations that add to
the complexity of data interpretation. For example, even though
Figure 2. Relationship between Three Fuel-Driven Metabolic Cycles that Generate Metabolic Coupling Factors in the b Cell
Glucose, FFAs, and glutamine (Gln) are metabolized in the b cell to provide substrates that enter the Krebs cycle, pyruvate cycle, and glycerolipid/FFA (GL/FFA)
cycle. Gln, via glutaminase, gives rise to glutamate (Glu), which is used by glutamate dehydrogenase (GDH) in themitochondrial matrix to produce a-ketoglutarate
(a-KG) that enters the Krebs cycle. GDH is allosterically activated by leucine (Leu). FFAs are rapidly activated to their corresponding CoA esters (FA-CoA) by
acyl-CoA synthase (ACS) enzymes present in different subcellular locations. FA-CoA is either oxidized to generate acetyl-CoA (Ac-CoA) or enters the GL/FFA
cycle. Glucose, via glucokinase (GK)-mediated formation of glucose-6-phosphate (G-6-P) and glycolysis, gives rise to pyruvate and Ac-CoA, which enters the
Krebs cycle. A substantial amount of pyruvate is also converted to oxaloacetate via the anaplerotic enzyme pyruvate carboxylase. This increases Krebs cycle
intermediates, including citrate, isocitrate, and malate, that are transported from the mitochondria to the cytoplam (cataplerosis). Glycolysis also contributes to
the formation of dihydroxyacetone phosphate (DHAP), which is reduced by glycerol-3-phosphate dehydrogenase using NADH, thus regenerating NAD+.
Glycerol-3-phosphate (Gro3P), thus formed, enters the GL/FFA cycle by reacting with FA-CoA, producing lysophosphatidic acid. Pyruvate participates in
pyruvate cycles that exchange substrates (citrate, isocitrate, andmalate) with the Krebs cycle. The pyruvate/citrate cycle, besides regenerating NAD+, also helps
in the formation of malonyl-CoA (MalCoA), which positively influences the GL/FFA cycle by diverting FA-CoA from b-oxidation into the GL/FFA cycle. All three
metabolic cycles generate MCFs that positively influence insulin granule exocytosis at different steps. The Krebs cycle and glycolysis contribute to the formation
of ATP that inhibits K+ATP channels, leading to Ca
2+ influx, which is essential for stimulus-secretion coupling needed for insulin exocytosis. The Krebs cycle also
generates NADH, which donates electrons to the mitochondrial electron transport chain (eTC), which produces ROS that stimulate insulin secretion. Pyruvate
cycling also generates NADPH that either directly or in combination with glutaredoxin or via ROS formation through the action of NADPH oxidase promotes insulin
granule exocytosis. The GL/FFA cycle produces several lipid signaling molecules, including FFA, FA-CoA, andMAG, all of which stimulate insulin secretion. MAG
likely activates Munc13-1, an exocytosis-promoting protein. The effectory MCFs are boxed in light blue, and the regulatory MCFs are boxed in yellow. A direct
and/or established action of a MCF is shown in solid arrows, whereas dashed arrows depict either indirect or yet-to-be-established actions. Blue lines indicate a
positive modulation, and the red line indicates negative effects. Enzymes, pathways, and involved proteins are shown in green.
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mediator of GIIS, it has not been possible to demonstrate
convincingly that it functions as a coupling factor modulating
KATP channels. This largely overlooked fact is illustrated by the
many studies that showed dissociations between GIIS and
rodent islet or b cell line ATP contents (Doliba et al., 2007;
Prentki, 1996). This is exemplified by results from the detailed
analysis of ATP, ADP, AMP, inorganic phosphate and phospho-
creatine levels measured in b cell-enriched cores of pancreatic
islets microdissected from freeze-dried pancreas (Ghosh et al.,
1991) and sampled at different intervals after switching the
glucose concentration from 4 to 8.3 mM during perfusion. In
this unique isolated perfused rat pancreas study, glucose stimu-lation (from 4 to 8.3 mM) in the presence of a physiological amino
acid mixture resulted in a very marked stimulation of insulin
release without detectable changes in either ATP or ADP con-
tents (Ghosh et al., 1991). Also, on theoretical grounds, one
cannot alter ATP in a cell without changing the activity of count-
less pathways and signaling events, and KATP channels are
modulated by numerous other metabolites. Similarly, changing
the cellular redox state results in concomitant changes in
adenine nucleotide levels and phosphate potential, ROS pro-
duction, the operation of many pathways, and, as a result,
perturbations of numerous signaling events. Progress in our
understanding of FIIS must come from several approaches
that are expected to converge in a consensus view. This reviewCell Metabolism 18, August 6, 2013 ª2013 Elsevier Inc. 165
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field, indicates where we still lack information, and presents
a consensus view obviously influenced by our personal
perspective.
Metabolic Coupling Factors: Definition and
Classification
Two observations demonstrate that KATP/Ca
2+ signaling is not
the whole answer for stimulus-secretion coupling in GIIS. The
first observation is pharmacological. Thus, GIIS can be elicited
with normal concentration dependency over an elevated
baseline when the KATP channels are bypassed by combining
diazoxide (which opens and eliminates the control of these
channels by ATP) with depolarizing concentrations of KCl (that
persistently elevate cytosolic Ca2+) (Aizawa et al., 1998; Hen-
quin, 2000). The second observation is genetic. It came as a
surprise that isolated islets from mice with knockout (KO) of
either SUR1 (regulatory subunit of the KATP channel and the
target of sulfonylureas) or Kir6.2 (the inwardly rectifying KATP
channel subunit) can respond to high glucose with augmented
insulin secretion, albeit with altered charateristics and patterns,
and that these animals show near-normal glucose homeostasis
(Ravier et al., 2009; Szollosi et al., 2007). Complementing these
results is the much-reduced glucose responsiveness of islets
from SUR1 KO mice, a defect that is reversed by acetylcholine
or GLP-1 (Doliba et al., 2004), demonstrating the critical partici-
pation in GIIS of amplification processes that are linked to clas-
sical second messengers. It can be concluded that an increase
in Ca2+ levels is regulatory for secretion and permissive for the
action of additional MCFs besides ATP and ADP.
There is evidence that intermediates and cofactors arising
from glucose, amino acid, and lipid metabolism exert their
effects on different targets and influence secretion at various
steps. Such effects can be at the terminal step of insulin granule
and plasma membrane fusion (exocytosis), at earlier steps, such
as granule movement and recruitment and changes in ion
channels activities, or at key upstream metabolic processes.
Therefore, depending on the timing of the action of the metabo-
lites in the overall signaling cascade, metabolic signals have
been viewed as either early or late, but this distinction is difficult
to maintain. To date, the term MCF has been used broadly,
which has contributed to confusion regarding its meaning. We
propose the following more specific definition: a metabolic
coupling factor is a signal that plays an essential, but not neces-
sarily sufficient, role in nutrient-induced secretion either because
it is a regulator of metabolic pathways crucially involved in the
fuel signaling cascade or because it is an effector modulating
the activity of key plasma membrane signaling proteins or the
exocytotic machinery. Thus, two types of MCFs can be defined:
(1) the regulatory MCFs (R-MCFs) modulate key metabolic path-
ways and networks involved in FIIS, and (2) the effectory MCFs
(E-MCFs) are directly involved in the triggering and amplification
arms of FIIS (Figure 1). This concept is illustrated in Table 1 for
the MCFs proposed in the literature. In later sections, we will
assess their roles in FIIS.
Current Consensus View of the Metabolic Basis of GIIS
Besides KATP/ Ca
2+ signaling, the precise mechanisms of GIIS
are not fully understood. Nonetheless, sufficient knowledge166 Cell Metabolism 18, August 6, 2013 ª2013 Elsevier Inc.has been collected in the last few decades to build a consensus
view of the role played by key enzymes, pathways, and down-
stream signaling events in the signal cascade. The most relevant
roles are described in Figure 1.
Flux through the glucose sensor glucokinase is limiting for
GIIS, and the activity of this enzyme sets the pace of insulin
secretion as a function of blood glucose concentration
(Matschinsky, 1996). Glycolysis in the b cell is tightly coupled
to mitochondrial oxidative metabolism through nicotinamide
adenine dinucleotide (NADH) shuttles, in particular the glyc-
erol-3-phosphate and malate/aspartate shuttles, that transfer
glycolysis-derived reducing equivalents to mitochondria for
ATP generation (Jitrapakdee et al., 2010). In this process, these
shuttles allow NAD+ regeneration in the cytosol for sustaining
glycolytic flux. The activation of mitochondrial metabolism is
key for fuel signaling not only via the pyruvate dehydrogenase-
mediated production of acetyl-CoA for enhanced Krebs cycle
activity and ATP production, but also for the generation of addi-
tional signals involved in the amplification arms of GIIS (Maechler
et al., 2010). The central process in this respect is anaplerosis
(the replenishment and rise in Krebs cycle intermediates), largely
mediated by pyruvate carboxylase (Prentki, 1996). This enzyme
produces oxaloacetate, which allows a rise in mitochondrial
citrate and downstream citric acid cycle intermediates, following
condensation of oxaloacetate with acetyl-CoA by citrate
synthase.
For amino acid-induced secretion, the preeminent anaplerotic
enzyme is mitochondrial glutamate dehydrogenase (GDH),
which catalyzes the oxidative deamination of glutamate to
a-ketoglutarate (Gao et al., 1999; Li et al., 2011; Maechler
et al., 2010). It works in tandem with glutaminase, which cata-
lyzes the deamination of glutamine to glutamate. Gain of function
of GDH is associated with a form of hyperinsulinemic hypogly-
cemic syndrome characteristically provoked by protein meals
(de Lonlay et al., 2005; Hsu et al., 2001; Li et al., 2011; Maechler
et al., 2010).
The central role of anaplerosis stems from the fact that once
elevated, some Krebs cycle intermediates (in particular citrate)
not only have a catalytic role in cycle activity, but they can also
be used in other pathways linked to production in the cytoplasm
of a number of candidate R-MCFs (e.g., citrate, malonyl-CoA,
glutamate) or E-MCFs (eg., NADPH) (Figures 2 and 3). This re-
quires the quantitative exit of some cycle intermediates from
the mitochondrial matrix to the cytoplasm (cataplerosis) (Farfari
et al., 2000) via transporters such as the di- and tricarboxylate
carriers. Once in the cytoplasm, some Krebs cycle intermediates
(citrate, isocitrate, a-ketoglutarate, and malate) enter pyruvate
cycling processes (Jensen et al., 2008; Jitrapakdee et al.,
2010) (discussed below) that generate cytoplasmic NADPH.
The gamma-aminobutyric acid (GABA) shunt (Figure 3), driven
also by anaplerotic events, generates succinate from glutamate,
bypassing a-ketoglutarate dehydrogenase (Li et al., 2008;
Pizarro-Delgado et al., 2010). This shunt is activated in b cells
by high glucose, producing GABA and gamma-hydroxybutyrate,
which function as paracrine inhibitors of a cells, thus contributing
to glucose suppression of glucagon secretion (Li et al., 2013).
Human and rodent b cells contain high amounts of GABA, and
the release of GABA from these cells, promoted by elevated
glucose, is part of an autocrine and paracrine positive feedback
Figure 3. Anaplerotic- and Cataplerotic-Derived Signals for Insulin Secretion
Glucose-derived pyruvate in the b cell participates in three pyruvate cycling processes that exchange substrates with the Krebs cycle: the pyruvate/citrate,
pyruvate/malate, and pyruvate/phosphoenolpyruvate (PEP) cycles. Besides the pyruvate cycles, the isocitrate/a-KG shuttle also participates in this exchange.
These exchanges of substrates between the cytosol and mitochondria contribute to anaplerosis (formation and rise in Krebs cycle intermediates) and
cataplerosis (egress of Krebs cycle intermediates from the mitochondrion to the cytoplasm). PEP in the cytosol is used by pyruvate kinase (PK) to generate ATP
and pyruvate, which enters mitochondria. Inside mitochondria, almost half of pyruvate is oxidized to AcCoA, and the other half is converted to oxaloacetic acid
(OAA) (anaplerosis). AcCoA and OAA together give rise to citrate, which enters the Krebs cycle. Citrate either continues with the next step in the Krebs cycle or
participates in pyruvate/citrate cycling. In the pyruvate/citrate cycle, citrate leaves the mitochondria and is used by ATP-citrate lyase (ACL) in the cytosol to
produce AcCoA and OAA. In the cytosol, AcCoA is converted to MalCoA, and OAA is reduced by cytosolic malate dehydrogenase (MDH) to malate and NAD+. In
the cytosol, malate is converted to pyruvate by malic enzyme-1 (ME1), which also generates NADPH. In the pyruvate/malate cycle, mitochondrial OAA is
transformed to malate that is transported to the cytoplasm, and then cytosolic malate is transformed to pyruvate, which enters mitochondria, where it is
carboxylated to formOAA. In the pyruvate/phosphoenolpyruvate cycle, OAA is transformed to PEP using GTP via amitochondrial PEP-carboxykinase isoenzyme
(PEPCKm). PEP translocates to the cytoplasm to produce ATP plus pyruvate and then oxaloacetate. In the isocitrate/a-KG shuttle, isocitrate escapes the
mitochondria and is transformed to cytosolic a-KG plus NADPH via the IDH1, and then a-KG is transported to the mitochondria. In mitochondria, IDH3 is the
predominant Krebs cycle enzyme, which forms a-KG from isocitrate, generating NADH. The possibility exists that mitochondrial NADPH formed by nicotinamide
nucleotide transhydrogenase (NNT), using the H+ gradient across the inner membrane, is utilized by IDH2, which forms isocitrate from a-KG (i.e., the reverse
reaction of IDH3). Isocitrate then enters the cytosol and becomes a substrate for IDH1, which forms NADPH in the cytosol. Thus, isocitrate can act as a carrier of
NADPH across the mitochondrial membrane. In the GABA shunt, Glu, which is formed from Gln, gives rise to a-KG in the cytosol via a transaminase and in the
mitochondria via GDH. In mitochondria, Glu can enter the GABA shunt via glutamate decarboxylase (GAD). GABA can leave mitochondria and the b cells and
potentially exerts autocrine and paracrine effects on insulin secretion. GABA is further metabolized to succinic semialdehyde (SSA) and then succinate, which
enters the Krebs cycle. Candidate MCFs are highlighted in green.
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(Braun et al., 2012; Xu et al., 2006). Hence, anaplerosis in the b
cell is also linked via GABA to both enhanced insulin secretion
and reduced glucagon release.
An important feature of glucose metabolism is that it is tightly
linked to the production of lipid signaling molecules. This occurs
not only via enhanced membrane phospholipid metabolism
turnover, such as phosphoinositide breakdown and synthesis
(Morgan et al., 1985; Prentki and Matschinsky, 1987; Rana
et al., 1986; Wolf et al., 1988), but also via additional pathways.Although these pathways are not firmly established, they likely
include the malonyl-CoA/carnitine palmitoyltransferase I/fatty
acyl-CoA metabolic signaling network and the glycerolipid/free
fatty acid (GL/FFA) cycle, which tightly link glucose and fatty
acid metabolism to signaling for secretion (Nolan et al., 2006a;
Prentki and Madiraju, 2008, 2012). Thus, the emerging view
indicates that three interlinked metabolic cycles play essential
roles in insulin secretion promoted by glucose, FFAs, and amino
acids: the Krebs cycle, pyruvate cycling, and the GL/FFA cycle
(tricycling model) (Nolan and Prentki, 2008) (Figures 2 and 4).Cell Metabolism 18, August 6, 2013 ª2013 Elsevier Inc. 167
Figure 4. The GL/FFA Cycle and Lipid Signaling for Insulin Secretion
The GL/FFA cycle consists of two segments: lipogenesis (enzymes shown in green) and lipolysis (enzymes shown in blue). Glucose via glycolysis gives rise to
Gro3P, which is the backbone for glycerolipids. FFAs entering the cell are activated to FA-CoA by long-chain acyl-CoA synthase (ACSL) present on the surface of
both themitochondrial outermembrane and the endoplasmic reticulum (ER). FA-CoA is used to esterify Gro3P to form lysophosphatidic acid (LPA), by glycerol-3-
phosphate acyltransferases (GPATs) located on both the ER andmitochondrial surfaces. Further esterification of LPA to phosphatidic acid (PA) is mostly done on
ER by acylglycerolphosphate acyltransferase (AGPAT) isoenzymes. Lipin enzymes, which are distributed in lipid droplets, ER, nucleus, and cytosol convert PA to
1,2-diacylglycerol (1,2-DAG). Acylation of 1,2-DAG to triglyceride (TG), the final step of the lipogenic segment, is accomplished by diacylglycerol
acyltransferase-1 and diacylglycerol acyltransferase-2 (DGATs) present on the ER and lipid droplets. The lipolytic segment is initiated by adipose triglyceride
lipase (ATGL), which hydrolyzes TG to DAG. TG hydrolysis by ATGL is facilitated by perilipin and comparative gene identification-58 (CGI-58) protein on the
surface of lipid droplets. ATGL generates either 2,3-DAG or 1,3-DAG from TG, depending onwhether it is activated by CGI58 or not. DAG is hydrolyzed toMAGby
hormone-sensitive lipase (HSL), whose activity is facilitated by perilipin. Hydrolysis of 1,3-DAG and 2,3-DAG by HSL produces 1(3)-MAG and 2-MAG,
respectively. Hydrolysis of MAG to glycerol and FFAs in b cells is accomplished mostly by the plasma membrane-associated a/b-hydrolase domain containing 6
(ABHD6), and also to a lesser extent by MAG lipase. Glycerol is not further metabolized in the b cell and leaves the cell via aquaglyceroporins (AQPs). Nearly
50%–70% of the FFA released during lipolysis is recycled into lipogenesis after its activation to FA-CoA by ACSL. FA-CoA can also enter mitochondria via the
MalCoA-sensitive CPT-1 and carnitine system for b-oxidation (off signal for insulin secretion). MalCoA inhibition of CPT-1 can thus divert FA-CoA from b-oxidation
into the GL/FFA cycle that generates lipid signals for insulin secretion. The GL/FFA cycle-generated signals include (1) FA-CoA, which targets K+ATP channels and
is used for acylation of certain proteins; (2) LPA, which targets Edg2 receptors and influences Ca2+ levels, NFkB signaling, and peroxisomal proliferator-activated
receptor-g (PPARg); (3) PA, which binds to mammalian target of rapamycin (mTOR) and affects its activity and influences exocytosis; (4) 1,2-DAG, which binds
and activates exocytosis-promoting protein Munc13-1, protein kinase C (PKC), and protein kinase D (PKD); (5) 1(3)-MAG, which binds and activates Munc13-1;
and (6) FFA, which activates GPR40 and GPR120.
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brane receptors that sense the level of particular calorigenic nu-
trients. The FFA receptor GPR40/FFAR1 is highly expressed in b
cells and mediates approximately half of FFA-induced secretion
(Ferdaoussi et al., 2012; Kebede et al., 2008; Latour et al., 2007;
Nolan et al., 2006b), the remaining fraction likely requiring FFA
metabolism. Recent studies documented the existence of sugar
and amino acid receptors in b cells. The sweet taste receptor
T1R2 may participate in fructose-induced potentiation of GIIS
(Kyriazis et al., 2012), and amino acid taste receptors (Tas1R1/
Tas1R3 or umami) may in part mediate the action of glutamate
and arginine on insulin secretion (Oya et al., 2011). The contribu-168 Cell Metabolism 18, August 6, 2013 ª2013 Elsevier Inc.tion of sweet and amino acid taste receptors to insulin secretion
by this class of nutrients remains to be established. Only intra-
cellular pathways implicated in fuel-induced secretion are dis-
cussed in this review.
Anaplerotic- and Cataplerotic-Derived Signals
There is overwhelming evidence that pyruvate metabolism via
pyruvate carboxylase (PC) is central to b cell activation by
glucose. PC is highly expressed in the b cells (MacDonald,
1995; Schuit et al., 1997), and its level is as high as in gluconeo-
genic and lipogenic tissues (i.e., liver, adipose). However, the
islet tissue is not gluconeogenic, and therefore b cell PC has
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correlated with the dose dependence of GIIS (Cline et al.,
2004; Farfari et al., 2000). This does not reduce the role of pyru-
vate decarboxylation and oxidation in GIIS, as demonstrated
using a b cell-specific pyruvate dehydrogenase deficiency
approach (Srinivasan et al., 2010). The PC inhibitor phenylacetic
acid curtails GIIS (Farfari et al., 2000). PC small interfering RNA
(siRNA) knockdown impairs GIIS in both INS-1 cells (Hasan
et al., 2008) and rat islets (Xu et al., 2008a), while overproduction
of PC in INS-1 cells increases GIIS (Xu et al., 2008a). Finally, PC
expression is markedly reduced in islets from T2D patients
(MacDonald et al., 2009b) and various rodent models of T2D
(Han and Liu, 2010; Jensen et al., 2008) that show impaired
GIIS. Besides formation of oxaloacetate by PC, the oxidative
deamination of glutamate to a-ketoglutarate by mitochondrial
GDH is also a significant contributor to anaplerosis by amino
acids, as discussed below in the section on glutamate (Maechler
et al., 2010).
Anaplerotic Pyruvate Cycling
Pyruvate enters threepyruvatecyclingprocesses involvingKrebs
cycle intermediates (citrate, malate, and isocitrate) aswell as one
involving phosphoenolpyruvate; these cycles form the crux of
anaplerosis- cataplerosis-derived signaling events and MCF
production (Jensen et al., 2008; Jitrapakdee et al., 2010; Nolan
and Prentki, 2008) (see detailed pathways in Figure 3). The first
three cycles produce NADPH in the cytosol using mitochondrial
NADH. They have been termed the pyruvate/citrate, pyruvate/
malate, and pyruvate/isocitrate cycles.
The pyruvate/citrate cycle is likely important for GIIS (Farfari
et al., 2000; Flamez et al., 2002; Guay et al., 2007). Thus, PC con-
verts approximately 50%of the pyruvate to oxaloacetate in b cell
mitochondria (Cline et al., 2004), citrate levels in both cytosol and
mitochondria are elevated in proportion to glucose concentra-
tion (Farfari et al., 2000; Schuit et al., 1997), and pharmacological
intervention at several steps of the pyruvate/citrate cycle causes
decreased GIIS in b cells (Jensen et al., 2008). In accordance
with this view, some (Guay et al., 2007), but not all (Brown
et al., 2009; Ronnebaum et al., 2008), studies showed reduced
GIIS following siRNA knockdown of ATP-citrate lyase (ACL)
and malic enzyme, which are components of this cycling pro-
cess. What makes the pyruvate/citrate cycle particularly attrac-
tive compared to the others is that it is the only one that allows, in
addition to NADPH production, the following: (1) the reoxidation
of NAD at the cytosolic malate dehydrogenase step required for
sustained glycolytic flux, (2) the transfer of acetyl-CoA from the
mitochondria to the cytoplasm to regulate many biological
processes (it is both an NADPH and acetyl-CoA shuttle), and
(3) the associated production of malonyl-CoA, a key R-MCF
controlling lipid partitioning. Another aspect of this cycle is that
it is likely linked to metabolic oscillations. Insulin release from b
cells is pulsatile and parallels oscillations in Ca2+, ATP, NAD(P)
H, and citrate levels (Corkey et al., 1988; Longo et al., 1991;
MacDonald et al., 2003a). Citrate is a strong allosteric modulator
of both phosphofructokinase, a key enzyme implicated in
glycolytic oscillation (Corkey et al., 1988), and acetyl-CoA
carboxylase, which produces malonyl-CoA.
In the proposed pyruvate/isocitrate cycle (Ronnebaum et al.,
2006), cytoplasmic isocitrate is converted to a-ketoglutarate
and NADP to NADPH by cytosolic isocitrate dehydrogenase(cIDH; IDH1). a-ketoglutarate can enter mitochondria, and its
C4 carbon derivative is transferred back to the cytosolic pyruvate
pool only via steps of the pyruvate/malate cycle. Thus, this cycle,
unlike the other two, is not an independent cycle and therefore
may not be termed an anaplerotic pyruvate cycling process. It
is rather a loop for the generation of cytosolic NADPH and a-ke-
toglutarate. We prefer to name it the a-ketoglutarate/isocitrate
shuttle. Alternatively, cIDH action can result in an off signal, as
this enzyme can catalyze the reverse reaction using cytosolic
NADPH and a-ketoglutarate to form isocitrate, which can enter
mitochondria, thus transporting NADPH-reducing equivalents
to mitochondria and depleting MCF levels in the cytosol. This
possible action of cIDH is discussed below under the heading
‘‘Emerging Negative and Decelerating Metabolic Pathways.’’
The third pyruvate cycling process is the pyruvate/malate
cycle (MacDonald, 1995). In accordance with its possible role
in metabolic signaling, several studies showed that silencing
cytosolic malic enzyme reduces GIIS (Guay et al., 2007;
Pongratz et al., 2007; Xu et al., 2008b). Mice express low levels
of islet cytosolic malic enzyme (ME-1 isoform) relative to rats
or humans (MacDonald et al., 2009a), and the Mod-1 mouse
that has a null mutation in the ME1 enzyme is phenotypically
normal (Lee et al., 1980). Because a critical step in the pyru-
vate/malate and pyruvate/citrate cycles is catalyzed by cytosolic
malic enzyme, it has been argued that these two cycles cannot
be important for GIIS (Jensen et al., 2008). We feel that this
cannot be concluded from these observations. Thus, perifused
mouse islets have amuch lower second phase of GIIS compared
to rat and human islets, and one study showed that mouse islets
contain an appreciable amount of malic enzyme (Xu et al.,
2008b). The amplification arms of GIIS likely involve many path-
ways; therefore, malic enzyme may not be absolutely necessary
for GIIS (the only necessary pathway being KATP/Ca
2+ signaling),
yet it still may play a role in this process by being a component of
one of the amplification arms.
A recent study (Stark et al., 2009) provided evidence for a
fourth pyruvate cycling process (the pyruvate/phosphoenolpyr-
uvate cycle) that is linked to GTP hydrolysis in the mitochondrion
and ATP production in the cytoplasm (Figure 3). This cycle is
further discussed below in the GTP section.
While there is a general agreement on the importance of
pyruvate cycling pathways in GIIS, there is some controversy
with regard to the relative importance of each (Jensen et al.,
2008; MacDonald et al., 2005a; Nolan and Prentki, 2008). A
plausible resolution of the argument may be found in the redun-
dancy of these three cycles, since all generate cytoplasmic
NADPH. Depending on the experimental conditions, one cycle
is more important than the others for GIIS.
Cytosolic NADPH
One of the first events following b cell stimulation by glucose is a
rise in total b cell NAD(P)H content (Pralong et al., 1990). This
phenomenon occurs prior to b cell depolarization, Ca2+ eleva-
tion, and the initiation of insulin release (Heart et al., 2007). There
is much support for a role of NADPH as an E-MCF. NADPH can
be produced by the pentose pathway; however, flux through this
pathway is low relative to total glucose utilization in sorted rat b
cells, and elevated glucose causes inhibition of this pathway,
perhaps because NADPH provided by other routes potently
inhibits glucose-6-phosphate dehydrogenase (Schuit et al.,Cell Metabolism 18, August 6, 2013 ª2013 Elsevier Inc. 169
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important for GIIS, which draws attention to other pathways, in
particular pyruvate cycling processes that can shuttle NADPH
from the mitochondrion to the cytoplasm.
Nicotinamide nucleotide transhydrogenase (NNT), a redox-
driven reversible proton pump of the mitochondrial inner
membrane, catalyzes the formation of NADPH in the matrix
(Figure 3). Interestingly, NNT mutant mice are glucose intolerant
and secrete less insulin during a glucose tolerance test (Freeman
et al., 2006). In addition, silencing of NNT in MIN6 cells results in
impaired GIIS (Freeman et al., 2006), whereas increased NNT
levels predispose cells to insulin hypersecretion (Wong et al.,
2010). Therefore, NNT appears to play a role in GIIS. While
NADPH formed by NNT is likely instrumental in mitochondrial
ROS detoxification, we suggest the following complementary
role of NNT andmitochondrial NADPH in GIIS. Themitochondrial
NADP-dependent IDH (IDH2), operating in the reverse direction,
consumes NADPH generated by NNT and converts a-ketogluta-
rate to isocitrate that leaves the matrix and is used by cytosolic
aconitase to form citrate (Figure 3). Cytosolic citrate then enters
the pyruvate/citrate cycling pathway, giving rise to cytosolic
NADPH, acetyl-CoA, and malonyl-CoA, as discussed in the sec-
tion dealing with pyruvate cycling.
Strong evidence supports a role for cytosolic NADPH in GIIS:
(1) the dose dependence of the NADPH/NADP ratio (based on
total content) correlates with GIIS in rodent islets and b cell lines
(MacDonald et al., 2006; Reinbothe et al., 2009); (2) NAPDH
directly promotes exocytosis in patch-clamped b cells, whereas
NADH does not (Ivarsson et al., 2005); and (3) RNAi silencing of b
cell cytosolic NADPH generating malic enzyme reduces GIIS
(Guay et al., 2007; Pongratz et al., 2007; Xu et al., 2008b).
Two molecular targets have been proposed for NADPH, The
first potential target is the redox protein glutaredoxin (GRX),
which requires NADPH to cycle its oxidixed and reduced states.
GRX participates in redox-regulated posttranslational modifica-
tion of many proteins, including exocytosis proteins (Ivarsson
et al., 2005). Microinjection of recombinant GRX1 potentiated
the effects of NADPH on exocytosis (Ivarsson et al., 2005), and
silencing or ovexpression of GRX1 in INS-1 (832/13) cells or rat
islets reduced or stimulated GIIS, respectively (Reinbothe
et al., 2009). A second potential target is the voltage-dependent
K+ (Kv) channel (MacDonald et al., 2003b). Kv channel activation
repolarizes glucose-stimulated action potentials and inhibits
Ca2+ entry through voltage-gated Ca2+ channels. Inhibition of
these channels is expected to enhance action potentials and
Ca2+ influx and to allow more sustained secretion induced by
glucose. The Kv b subunit contains an NADPH binding site,
which may be a sensor of the intracellular redox potential that
regulates the channel (Jitrapakdee et al., 2010). Direct testing
of this possibility is required.
Malonyl-CoA
Acetyl-CoA formed by ACL is carboxylated by acetyl-CoA
carboxylase (ACC) to malonyl-CoA, which is a key metabolite
that lies at the crossroad of glucose and fat metabolism.
Glucose-derived malonyl-CoA is the precursor for de novo
lipogenesis and fatty acid elongation and also controls the rate
of fatty acid oxidation via its allosteric inhibition of carnitine
palmitoyltransferase I (CPT-I), the limiting step of this pathway.
Much support has been provided for the hypothesis that170 Cell Metabolism 18, August 6, 2013 ª2013 Elsevier Inc.malonyl-CoA is a MCF for GIIS. Thus, the dose dependence of
GIIS tightly correlates with malonyl-CoA levels in the b cell, and
only fuels or combinations of fuel stimuli that increase malony-
CoA levels promote insulin release (Prentki et al., 1992).
Pharmacological inhibition of ACC reduces GIIS in INS cells
and islets (MacDonald et al., 2008). Overexpression of a mutant
CPT-1 that is insensitive tomalonyl-CoA in INS cells impairs GIIS
(Herrero et al., 2005). Overexpression of malonyl-CoA decarbox-
ylase in the cytoplasm reduces malonyl-CoA levels and lowers
GIIS in the presence (Roduit et al., 2004), but not in the absence,
of exogenous FFA (Mulder et al., 2001; Roduit et al., 2004).
The fact that malonyl-CoA decarboxylase overexpression
does not alter GIIS in the absence of exogenous FFAs has
been presented as an argument against a role for malonyl-CoA
in GIIS (Mulder et al., 2001). This argument can be refuted.
Thus, in the absence of exogenous FFA, the lipid amplification
arm of GIIS is likely to be sluggish or nonexistent because it re-
quires cytosolic FFA or fatty acyl-CoA (FA-CoA) to be generated.
In the absence of exogenous FFA, cytoplasmic FFA and FA-CoA
can only be derived from triglyceride stores, but these cellular
stores are likely to be depleted during isolation of islets and their
preincubation in the presence of a low concentration of glucose
as the only exogenous fuel. Glucose-derived glycerol-3-
phosphate and FFA-derived FA-CoA feed into the GL/FFA cycle
that is central to the generation of lipid signaling molecules, at
least in its lipolytic arm (see lipid signaling section below). Hence,
glucose and FFA need each other to work efficiently for FIIS. This
issue is revisited in a later section in which we discuss problems
of data interpretation as a function of the in vitro experimental
conditions.
Notably, the malonyl-CoA/FA-CoA/CPT-1 metabolic signaling
network also plays a role in the regulation of insulin sensitivity
and in hypothalamic nutrient sensing, participating in appetite
and body weight control (Hu et al., 2005). If the sole target of
malonyl-CoA is CPT-1, then this metabolite should be con-
sidered as a R-MCF. However, recent studies showed dynamic
protein malonylation and succinylation (Newman et al., 2012).
The possibility exists that acylation (malonylation) of late com-
ponents of the secretion machinery is implicated in FIIS.
Malonyl-CoA would thus qualify as an E-MCF as well.
Cytosolic Acetyl-CoA
Pyruvate/citrate cycling may play a role in GIIS, not only via the
generation of NADPH, malonyl-CoA, and NAD reoxidation, but
perhaps also via cytosolic acetyl-CoA production. An additional
asset of the pyruvate/citrate shuttle versus the other pyruvate
cycling processes is that it is not only an NADPH shuttle, but
also an acetyl-CoA shuttle, that transports mitochondrial
acetyl-CoA to the cytoplasm. The total b cell acetyl-CoA/CoA
ratio does not vary much with glucose levels (Prentki et al.,
1992), but this should not be taken as an argument to refute a
role of cytosolic acetyl-CoA in GIIS, because the cellular pool
of acetyl-CoA is compartmentalized and the contributions of
the mitochondrial and cytosolic acetyl-CoA fractions are not
known. Compatible with the possibility that cytosolic acetyl-
CoA may be a MCF is the following: pharmacological inhibition
of ACL (Flamez et al., 2002; Guay et al., 2007) and RNAi knock-
down of the enzyme reduced GIIS, particularly at intermediate
glucose and in the presence of exogenous FFA (Guay et al.,
2007). Some studies did not observe that silencing ACL reduces
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absence of exogenous FFA and at low and high glucose only.
In addition, very high glucose may override reduced flux through
ACL, an allosteric enzyme. Although there is no direct evidence,
it is attractive to speculate that cytosolic acetyl-CoA serves as a
MCF, as recent studies showed that many enzymes and
signaling molecules are dynamically acetylated to change their
activities (Scott, 2012).
Glutamate
The finding that glutamate directly stimulates insulin exocytosis
in permeabilized b cells prompted studies on the role of gluta-
mate andGDH in FIIS (Maechler andWollheim, 1999). Glutamate
can be produced during glucose metabolism from the Krebs
cycle intermediate a-ketoglutarate by reductive amination or
transamination (Bertrand et al., 2002). It can also be generated
from glutamine via glutaminase. Theoretically, at high glucose,
the elevated mitochondrial NADH-to-NAD ratio may promote
NAD(P)H-dependent reductive amination of a-ketoglutarate,
forming glutamate via GDH. However, the key question is that
of the direction of the flux through GDH under normal physiolog-
ical conditions and in the presence of high levels of glutamine
and glutamate, low levels of ammonia, and powerful regulators
of the enzyme. The evidence indicates that net flux is in the direc-
tion of oxidative deamination, i.e., glutamate to a-ketoglutarate
(anaplerosis), rather than in the opposite direction (cataplerosis)
(Kelly et al., 2002; Stanley, 2009). This view is supported by the
phenotype of patients with gain-of-function mutations of GDH,
which render GDH less susceptible to allosteric GTP and ATP
inhibition, leading to hyperinsulinemia with hypoglycemia
(Li et al., 2012b). In these patients, leucine- or protein-rich meals
cause severe bouts of hypoglycemia and hyperinsulinemia
(Stanley, 2009).
Is glutamate an E-MCF? The finding of most studies that
glucose stimulation enhances islet glutamate levels supports
the idea that glutamate is an E-MCF (Maechler and Wollheim,
1999; Vetterli et al., 2012). Furthermore, overexpression of gluta-
mate decarboxylase in b cells reduces glutamate levels and
insulin secretion. Finally, GIIS is reduced in islets from b cell-
specific GDH KOmice (Vetterli et al., 2012). However, glutamate
levels can be dissociated from insulin secretion, and glutamine,
which is rapidly transformed to glutamate, does not promote
secretion alone or in the presence of elevated Ca2+ (caused by
high KCl levels). These observations have been used to dismiss
the glutamate hypothesis (Jitrapakdee et al., 2010).
To reconcile these studies, we propose that glutamate may
function as a R-MCF rather than an E-MCF involving the
following pathways (see Figure 3). As a glutamine-derived sub-
strate for GDH, it will permit high levels of a-ketoglutarate in
the presence of glucose. Then, via the reversal of the mito-
chondrial isocitate dehydrogenase reaction (IDH-2 isozyme,
NADP dependent only) allowed by the combined high mito-
chondrial levels of a-ketoglutarate and NADPH (provided by
nicotinamide nucleotide transhydrogenase), glutamate will
permit ample production of isocitrate and citrate for pyruvate
cycling processes. In addition, glutamate may activate
acetyl-CoA carboxylase for malonyl-CoA production (Palanivel
et al., 2005). In other words, glutamate lies at the crossroads of
amino acid, glucose, and lipid metabolism and as such is
defined here as a R-MCF.In sum, glutamate as a substrate links amino acid, glucose,
and FFA metabolism and signaling, and the evidence suggests
that it is not an E-MCF, but rather a R-MCF. Further, there is
no doubt that GDH is a key enzyme in the b cell fuel-sensing
process. GDH, an amino acid sensor of the glutamine and gluta-
mate levels, is the ‘‘glucokinase’’ of amino acid (glutamine plus
leucine)-induced secretion.
GTP
Both mitochondrial and cytosolic GTP have been suggested to
be MCFs for FIIS (Kibbey et al., 2007). Glucose stimulation of b
cells promotes an elevation of GTP levels (Kibbey et al., 2007).
GTP is formed in the cytosol via nucleoside diphosphate kinase
from guanosine diphosphate (GDP) and ATP. It induces insulin
exocytosis in permeabilized b cells in a Ca2+-independent
manner, possibly via GTP-binding proteins. Thus, several small
G proteins play a role in insulin exocytosis (Kowluru, 2003). In
mitochondria, GTP is produced in the Krebs cycle via the GTP-
specific isoform of succinyl-CoA synthase (GTP-SCS). siRNA
silencing of b cell GTP-SCS reduces insulin secretion in associ-
ation with lowered b cell ATP levels and a suppression of the
glucose-induced Ca2+ rise (Kibbey et al., 2007). Interestingly, b
cell mitochondrial GTP may serve as a substrate for the M
isoform of GTP-dependent phosphoenolpyruvate carboxyki-
nase and be part of a phosphoenolpyruvate cycling process
that is active in this cell type and perhaps involved in GIIS
(Stark et al., 2009). Additional work is needed to assess the
role of GTP and the proposed pyruvate/phosphoenolpyruvate
cycle (Figure 3) in insulin secretion.
Electron Transport-Derived Signals
Krebs cycle activation is coupled to the transfer of electrons to
the mitochondrial respiratory chain, resulting in the genera-
tion of ATP. Inhibition of various complexes of the electron
transport chain (ETC) abolishes GIIS, and there is ample evi-
dence that the mitochondrial ETC plays a role in generating
additional signals for secretion besides ATP. These potential
ETC-derived signals include ROS and reduced cytochrome c.
Nutrient-derived NADH and flavin adenine dinucleotide
(FADH) primarily regulate the flux of the b cell ETC via a
push (substrate) mechanism (Matschinsky et al., 1986a), but
additional factors derived from fuel activation regulate b cell
mitochondrial ETC activity and ATP production. These include
mitochondrial matrix ADP (Civelek et al., 1996), Ca2+ (Wieder-
kehr et al., 2011), GTP (Kibbey et al., 2007), alkalinization
(Wiederkehr et al., 2009), and the fission and fusion states of
this organelle (Liesa and Shirihai, 2013; Molina et al., 2009;
Park et al., 2008).
Recent work has provided pharmacological evidence for the
presence of an additional electron transport system in the b
cell (Gray and Heart, 2010). The transplasmamembrane electron
transport system (t-PMET) is analogous to the mitochondrial
ETC. It is a ubiquitous system that contains cytochromes and
enzymes bound to both the cytosolic and external side of the
plasma membrane and transmembrane proteins (Del Principe
et al., 2011; Gray et al., 2011). It oxidizes cytosolic NADH and
NADPH and passes electrons to a number of extracellular
targets and to oxygen to produce ROS. Elevated glucose may
activate t-PMET in the b cell, and it has been proposed that it
plays a role in GIIS (Heart et al., 2012). This idea is attractive inCell Metabolism 18, August 6, 2013 ª2013 Elsevier Inc. 171
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tosis occurs.
Adenine Nucleotides: ATP, ADP, AMP, and cAMP
The overall regulation of K+ATP channels by adenine nucleotides
depends on the net inhibitory effect of ATP on Kir6.2 and the acti-
vating effect of MgADP on the SUR1 component of the channel
(Drews et al., 2010; Proks et al., 2010). At high glucose, ADP level
is reduced, which contributes to KATP channel closure. ATP is
necessary for the priming steps of exocytosis, but whether vari-
ations of ATP directly regulate exocytotic proteins is not known.
With respect to phasic GIIS, recent work suggests that a second
phase in ATP increase occurs coincidently with second-phase
secretion (Tarasov et al., 2013; Wiederkehr et al., 2011).
Elevated glucose lowers the AMP/ATP ratio in the b cell (da
Silva Xavier et al., 2003), and this important energy parameter
may have consequences on a number of enzymes, particularly
the fuel sensor AMP-activated protein kinase (AMPK), which
negatively regulates insulin secretion (da Silva Xavier et al.,
2003; Fu et al., 2013; Salt et al., 1998). A low AMP-to-ATP ratio
will result in low AMPK activity that may favor insulin secretion.
The role of AMPK in b cell signaling is further discussed below.
Some evidence indicates that variation in the level of ATP is
coupled to changes in cAMP concentrations in b cells (Takahashi
et al., 1999). This is possible since some isozymes of adenylate
cyclase are activated by Ca2+ and show a KM for ATP close to
1 mM (Ramos et al., 2008), which is in the range of ATP concen-
trations thought to occur close to the plasma membrane
(Ainscow and Rutter, 2002). Cytosolic ATP appears to directly
enhance the major fast component of Ca2+-dependent exocy-
tosis of insulin granules, and this effect requires activation of
cAMP-dependent protein kinase (PKA) (Seino and Shibasaki,
2005). The pulsatility of insulin secretion by the b cell correlates
with oscillations in cytoplasmic Ca2+ and cAMP levels, both of
which are directly controlled by glucose metabolism (Dyachok
et al., 2008). Several recent studies showed that, besides PKA,
exchange protein directly activated by cAMP 2 (Epac2) is also
involved in cAMP-stimulated insulin secretion (Dzhura et al.,
2011; Kwan et al., 2007; Shibasaki et al., 2007). It appears that
while both PKA and Epac2 are players in the cAMP-mediated
increase in insulin secretion (Hatakeyama et al., 2007), pulsatility
of the secretion is dependent on Epac2 (Idevall-Hagren et al.,
2010). Significant evidence suggests that Epac2 exerts its
effects on secretion by activating small GTPase-Rap1 (Shibasaki
et al., 2007) and by interacting with the exocytotic proteins Rim2
(Yasuda et al., 2010) and synaptosomal-associated protein 25
(SNAP-25) (Vikman et al., 2009). Thus, cAMP exerts its effects
as an E-MCF by activating PKA and Epac2 and targeting a
number of channels and different components of the exocytotic
machinery.
Reactive Oxygen Species
ROS include superoxide (O2
d–), the hydroxyl radical (OHd), and
hydrogen peroxide (H2O2) (Maechler et al., 2010). These interme-
diates are highly reactive and can damage cells when present
above threshold levels. However, at relatively low concentra-
tions, ROS are signals in various cellular processes (Maechler
et al., 2010). The toxic roles of ROS in b cell dysfunction have
been widely studied and will not be discussed here. The cellular
levels of ROS are tightly regulated to prevent their accumulation
(Gehrmann et al., 2010; Maechler et al., 2010; Robertson and172 Cell Metabolism 18, August 6, 2013 ª2013 Elsevier Inc.Harmon, 2007). Superoxide is converted to less-reactive H2O2
by superoxide dismutase (SOD) and then to water by catalase
and glutathione peroxidase, a pathway providing defense
against oxidative stress. Interestingly, islet tissue contains
particularly low levels of antioxidant enzymes compared to other
tissues, suggesting a role for ROS as signalingmolecules in insu-
lin secretion (Newsholme et al., 2009).
Mitochondrial ETC components are major sites for ROS
formation at the level of complex I and the interface of ubiqui-
none and complex III (Maechler et al., 2010). ROS are produced
physiologically in cells during nutrient oxidation. Besides
mitochondria, ROS are produced by the plasma membrane
electron-transporting NADPH oxidase complex that is activated
by Ca2+ (Newsholme et al., 2009), by the t-PMET (Gray et al.,
2011), and in peroxisomes during fat oxidation. The relative
contribution of each of these pathways to b cell ROS production
during physiological variations in fuel levels is not known. In
mitochondria, nicotinamide nucleotide transhydrogenase, which
produces NADPH, contributes to ROS detoxification, and
altered activity of this enzyme is associated with changes in
insulin secretion (Freeman et al., 2006; Wong et al., 2010). This
indicates that critical regulation of ROS levels, possibly linked
to GIIS, takes place in the mitochondrial compartment.
Several studies have provided evidence for a role of ROS, in
particular H2O2, in GIIS (Newsholme et al., 2009; Pi et al.,
2007). Unlike superoxide, hydrogen peroxide is more stable,
uncharged, and is a diffusible molecule that is rapidly synthe-
sized and degraded. This better meets the criteria of a
messenger molecule. Support for a role for ROS in GIIS stems
from a number of observations. (1) Several studies showed
that a rise in glucose causes ROS elevations, particularly H2O2,
in rodent islets and b cell lines (Pi et al., 2007; Rebelato et al.,
2011). (2) The rise in ROS and insulin secretion is reduced by
pharmacological ROS scavengers (Leloup et al., 2009). (3) Low
micromolar H2O2 stimulates insulin secretion, and the effect is
curtailed by ROS scavenging strategies (Pi et al., 2007). (4)
External production of superoxide via the xanthine/xanthine
oxidase system promotes insulin release from rat islets (Gray
and Heart, 2010). (5) Overexpression of antioxidant enzymes
reduces GIIS (Pi et al., 2007). However, some data argue against
a role for ROS in GIIS. One study showed that elevated glucose
reduces islet ROS production (Martens et al., 2005) and that
reduced production of superoxide in islets from NADPH oxidase
(NOX2) KO mice is associated with enhanced GIIS (Li et al.,
2012c). In addition, overexpressing H2O2-inactivating catalase
in rat islet or INS1-E cells does not affect GIIS (Lortz et al.,
2013). As mentioned above, catalase is one of those genes
whose expression is disallowed in islets (Thorrez et al., 2011).
A difficulty in this area is that cells that are fuel deprived at low
glucose levels may show metabolic stress with enhanced ROS.
In addition, to our knowledge, all studies so far reported ROS
measurements at low and high glucose only, without showing
a tight correlation between the dose dependence of GIIS and
ROS levels. Another methodological difficulty lies in the fact
that dyes used for ROS measurements lack specificity.
The precise ROS targets in the b cell for insulin secretion have
not been identified. To reconcile some data in the literature, it can
be speculated that H2O2 and O2
d– are positive and negative
signals for GIIS, respectively. Thus, there is some evidence
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ROS can have opposite effects: stimulating secretion when con-
centrations are low, but causing b cell dysfunction when chron-
ically produced in high amounts.
Reduced Cytochrome c
A primarily pharmacological study suggested that a single
component of the mitochondrial ETC (reduced cytochrome c)
acts as an E-MCF for insulin secretion (Jung et al., 2011). Cyto-
chrome c is a mobile protein of the ETC that is released in the
cytoplasm under proapoptotic conditions. Its reduced state is
linked to the generation of ROS. Thus, GIIS in rat islets correlated
with reduced cytochrome c, and agents that caused cytochrome
c reduction promoted insulin secretion, even in the face of
reduced oxygen consumption. Stimulation of islets with various
fuel stimuli resulted in the appearance of cytochrome c in the
cytosol, raising the possibility of the regulation of FIIS by reduced
cytochrome c impinging on various pathways (e.g., protein
kinases, channels, exocytotic effectors) (Jung et al., 2011).
Inositol Lipids and Polyphosphates
Polyphosphoinositides
Phosphatidylinositol 4,5-bisphosphate (PIP2) and phosphatidyli-
nositol 3,4,5-trisphosphate (PIP3) are membrane component
and signaling lipids, whose levels vary upon cell stimulation by
various stimuli (Barker and Berggren, 2012). They regulate a
vast array of processes such as cell growth, the activity of
channels, remodeling of the actin cytoskeleton, and vesicle
trafficking (Saarikangas et al., 2010). Glucose rapidly enhances
the turnover of phosphoinositides in b cells (Barker and
Berggren, 2012; Prentki andMatschinsky, 1987), but it is unclear
whether they play a direct role in FIIS or an indirect role via
signaling molecules such as inositol 1,4,5-trisphosphate
(InsP3) and diacylglycerol.
Blocking PIP2 biological actions or reducing its level with
molecular approaches did not impact GIIS, although suscepti-
bility to apoptosis was increased. However, upregulating PIP2
production resulted in an altered filamentous actin (F-actin) cyto-
skeleton and insulin secretion in MIN6 b cells (Tomas et al.,
2010). Mice lacking the G protein-coupled PI3-kinase catalytic
subunit (p110g/) lack first-phase insulin secretion and show
a blunted second phase (Pigeau et al., 2009). p110g phosphor-
ylates PIP2 to generate PIP3, subsequently activating down-
stream targets. p110g appears tomodulate cortical actin density
and insulin granule localization to the plasma membrane. How-
ever, this isoform displays a constitutive activity and is not
glucose sensitive. Thus, the phosphoinositides play a permis-
sive, but not regulatory, role in GIIS.
Inositol Polyphosphates
Glucose stimulation of b cells enhances the production of
inositol-phosphate species, particularly InsP3, which mobilizes
Ca2+ from intracellular stores (Prentki and Matschinsky, 1987;
Rana et al., 1986; Wolf et al., 1988). The mechanism involves
activation of membrane-bound phospholipase C (PLC) by
Ca2+, which promotes the breakdown of PIP2, releasing InsP3.
Thus, the second messenger IP3, similar to cAMP, may
contribute in part to the glucose-induced Ca2+ rise and oscilla-
tions and, as such, is one of the E-MCFs of GIIS.
PLC-generated InsP3 production not only regulates Ca2+
mobilization in the b cell but is also the substrate for generatinghighly phosphorylated inositol phosphates such as InsP5,
InsP6, and the inositol pyrophosphate InsP7 (Illies et al., 2007).
InsP5 and InsP6 stimulate exocytosis and Ca2+ influx via
L-type Ca2+ channels in b cells. InsP6 also serves as a substrate
for the inositol hexakisphosphate kinases (IP6K1–IP6K3) to
become further phosphorylated to diphosphoinositol pentaki-
sphosphate (InsP7) (Barker and Berggren, 2012). Overexpres-
sion of IP6K1 or IP6K2 increased InsP7 levels and stimulated
Ca2+-induced insulin exocytosis from the readily releasable
pool in patch-clamped b cells, whereas siRNA knockdown of
IP6K1 impaired insulin exocytosis (Illies et al., 2007). Thus,
besides InsP3, some highly phosphorylated inositol polyphos-
phates may play a role in insulin exocytosis, but it remains to
be determined whether they act as MCFs for GIIS or play a
role as permissive factors.
Intracellular Lipid Signaling
Work by J.D. McGarry and colleagues established that the high
concentration of circulating FFA that accompanies food depriva-
tion is a sine qua non for efficient GIIS when a fast is terminated
(Dobbins et al., 1998; Stein et al., 1996). This was confirmed
ex vivo in rat islets (Stein et al., 1996). In addition, rodent islets
deprived of endogenous triglyceride (TG) stores barely secrete
insulin in response to glucose (Koyama et al., 1997), and
2-bromostearate, a fatty acid oxidation inhibitor, restores normal
GIIS in islets from fasted rats (Tamarit-Rodrı´guez et al., 1984).
Although there is general acceptance of the view that lipid
signaling plays an essential role in FIIS, the precise pathways
and lipid signaling molecules implicated in this process remain
uncertain. Glucose-derived carbons are metabolized via three
main pathways linked to the production of MCF: (1) glucose
oxidation, (2) anaplerosis, and (3) the provision of glycerol-3-
phosphate (Gro3P) for GL/FFA cycling, which emerges as an
essential process participating in GIIS.
GL/FFA Cycling
Gro3P is produced by cytosolic Gro3P dehydrogenase from
dihydroxyacetone phosphate (DHAP). A substantial portion of
total glucose utilization by islet b cells (about 30% in mouse islet
at elevated glucose levels) is via Gro3P incorporation into GL and
GL/FFA cycling (Peyot et al., 2010) (Figure 4). This process is part
of the collection of mechanisms of MCF production. Glucose
metabolism via Gro3P has an additional benefit for b cell function
since the metabolism of DHAP to Gro3P via cytosolic NAD+-
linked Gro3P dehydrogenase replenishes the NAD+ required
for fast glycolysis (Prentki and Madiraju, 2008) (Figure 4).
The GL/FFA cycle consists of the lipogenesis (esterification)
and lipolysis (hydrolysis) segments that generate many lipid
intermediates, some of which are signaling molecules: various
species of monoacylglycerol (MAG), DAG, phosphatidate, lyso-
phosphatidate, FA-CoA, and FFA (Prentki and Madiraju, 2008).
Lipogenesis starts with the successive esterification of
glycolysis-derived Gro3P with FA-CoA to produce lysophos-
phatidate and then phosphatidate by glycerophosphate acyl-
transferase and 1-acyl-sn-glycerol-3-phosphate acyltransferase
enzymes. Phosphatidate is dephosphorylated by lipins to pro-
duce sn1,2-DAG, used for the formation of TG by diacylglycerol
acyltransferase enzymes.
TG is stored in b cells as micro lipid droplets in the cytosol and
near the cell membrane (Pinnick et al., 2010). Lipolysis starts withCell Metabolism 18, August 6, 2013 ª2013 Elsevier Inc. 173
Cell Metabolism
ReviewTG hydrolysis by adipose triglyceride lipase (ATGL), which gen-
erates either sn2,3-DAG or sn1,3-DAG, depending onwhether or
not (respectively) it is associated with the activator protein CGI58
(Eichmann et al., 2012). It is important to note that ATGL does not
produce sn1,2-DAG, which is signaling competent. Both 2,3-
DAG and 1,3-DAG are acted upon by hormone-sensitive lipase
(HSL) to give rise to either 2-MAG or 1(3)-MAG. MAG hydrolysis
to glycerol and FFA completes the lipolytic segment of the
GL/FFA cycle. While both ATGL and HSL are present in
many tissues including b cells, MAG lipase, which breaks
down MAG to glycerol and FFA, is poorly expressed in b cells.
Our recent observations (S. Zhao, Y. Mugabo, J. Iglesias,
L. Xie, V. Delghingaro-Augusto, R. Lussier, M.-L. Peyot,
E. Joly, M.A. Davis, J.M. Brown, A. Abousalham, H. Gaisano,
S.R.M.M., and M.P., unpublished data) showed that MAG in b
cells is primarily hydrolyzed by membrane-bound a/b-hydrolase
domain containing 6 (ABHD6).
In comparison to a linear pathway, cyclic processes such as
the GL/FFA cycle are amenable to very tight and fast control.
Several lines of evidence strongly implicate the GL/FFA cycle
in the regulation of GIIS, particularly via its lipolysis arm:
(1) lipogenesis (FFA esterification, not de novo lipogenesis) and
lipolysis correlate with the dose dependence of GIIS (Prentki
and Madiraju, 2012); (2) GIIS is dose-dependently reduced by
pioglitazone in INS832/13 b cells with parallel reduction in
lipolysis (Lamontagne et al., 2009); (3) triacsin-C, an inhibitor of
FA-CoA synthase, inhibits the FFA amplification of GIIS (Roduit
et al., 2004); (4) inhibition of lipolysis with orlistat or 3,5-dimethyl-
pyrazole lowers GIIS (Masiello et al., 2002; Nolan et al., 2006a;
So¨rhede Winzell and Ahre´n, 2004); (5) the DAG lipase inhibitor
RHC80267 blocks GIIS in rat islets (Capito et al., 1989; Konrad
et al., 1994); (6) HSL is found in association with insulin granules
(Lindvall et al., 2004); (7) liver X receptor activation in human
islets and INS b cells increases GIIS accompanied by enhanced
GL/FFA cycling (Green et al., 2009; Ogihara et al., 2010); (8)
depletion of islet TG stores curtails GIIS (Koyama et al., 1997);
(9) siRNA knockdown of ATGL reduces GIIS (Peyot et al.,
2009); (10) GIIS is deficient in islets from both ATGL- and HSL-
deficient mice (Fex et al., 2009; Peyot et al., 2004, 2009); (11)
HSL deficiency exacerbates TG accumulation in leptin-deficient
ob/ob islets, leading to reduced GIIS (Sekiya et al., 2009); (12)
GL/FFA cycling is enhanced in compensating islets from obese,
nondiabetic, hyperinsulinemic Zucker fatty rats and is deficient in
diabetic islets from various rodent models with reduced GIIS
(Delghingaro-Augusto et al., 2009; Nolan et al., 2006a; Prentki
and Madiraju, 2012); and (13) functional ablation of PKCε
dramatically improves GIIS in rodent models of type 2 diabetes,
and the mechanism involves a shift in FFA partitioning toward
esterification and an increase in glucose-stimulated lipolysis
required for enhanced GIIS (Cantley and Biden, 2010; Cantley
et al., 2009).
What is the driving force of the GL/FFA cycle? Substrate avail-
ability is essential. The cycle is fed by Gro3P derived from the
glycolytic intermediate DHAP and by FA-CoA derived from
FFA. Islet DHAP increases upon glucose stimulation (Mat-
schinsky et al., 1986a), and exogenous FFA elevates FA-CoA
in b cells (Prentki et al., 1992). Covalent modification of key
enzymes of the GL/FFA cycle is also likely involved. In other
cell types, the activity of glycerol-3-phosphate acyltransferase174 Cell Metabolism 18, August 6, 2013 ª2013 Elsevier Inc.is inhibited by AMPK, whereas HSL is activated by cAMP-
activated protein kinase A (Prentki and Madiraju, 2008). Glucose
reduces AMPK activity and enhances cAMP production in the b
cell. It can be hypothesized that these enzymes are similarly
regulated in the b cell and that glucose enhances the cycle
activity both via substrate availability and changes in the phos-
phorylation state of these enzymes.
What is the interaction between the GL/FFA cycle and the
malonyl-CoA/CPT-1/FA-CoA network? Unless glucose is
elevated, lipid signaling molecules do not accumulate within
the b cell because they are depleted by fatty acid oxidation, an
off signal in lipid signaling. Indeed, fasting enhances b-oxidation
in islets due to a peroxisomal proliferator-activated receptor-
a-dependent upregulation of fat oxidation genes (Gremlich
et al., 2005). Thus, fasting upregulates the offmechanism of lipid
signaling. By contrast, activation of the fuel responsive GL/FFA
cycle is an onmechanism for secretion. Elevated glucose, occur-
ring in the fed condition, enhances GL/FFA cycling by increasing
malonyl-CoA that inhibits b-oxidation (inhibiting the off mecha-
nism), providing Gro3P for the esterification arm of the cycle,
and activating lipolysis via covalent modification of lipolytic
enzymes. Amino acids, by enhancing anaplerosis and malonyl-
CoA production, and exogenous FFA, by providing substrate
for the GL/FFA cycle, act together with glucose to promote
GL/FFA cycle activity and MCF production. Thus, the malonyl-
CoA/FA-CoA-GL/FFA cycle metabolic signaling network likely
plays an integrating role in modulating insulin secretion in
response to all classes of fuel stimuli to adjust insulin
secretion as a function of the nutritional state (Prentki and
Madiraju, 2012).
Lipolysis-Derived Signals: DAG, MAG, FFA, and FA-CoA
Much progress has been made recently in our understanding of
the stereospecificity of lipolytic enzymes. ATGL does not pro-
duce the signal-competent sn1,2-DAG that activates C kinases.
Rather, it produces 1,3-DAG and 2,3-DAG, which have no
ascribed signaling function (Eichmann et al., 2012). HSL primarily
hydrolyzes DAG at its 1 or 3 position, thus producing 1-MAG,
2-MAG, or 3-MAG, and under physiological condition it is not a
major TG hydrolase (Eichmann et al., 2012). In light of these con-
siderations and because HSL knockdown does not enhance, but
instead reduces, GIIS, it is unlikely that DAG is the lipolysis-
derived signal of fuel signaling, as was thought previously. Our
recent work indicates that genetic or siRNA knockdown of the
MAG hydrolase ABHD6 enhances GIIS, whereas overexpressing
ABHD6 reduces GIIS in the b cell (S. Zhao, Y. Mugabo,
J. Iglesias, L. Xie, V. Delghingaro-Augusto, R. Lussier, M.-L.
Peyot, E. Joly, M.A. Davis, J.M. Brown, A. Abousalham,
H. Gaisano, S.R.M.M., and M.P., unpublished data). Pharmaco-
logical inhibition of ABHD6 causes MAG accumulation and stim-
ulates insulin secretion both in vitro and in vivo. Thus, we now
think that MAG, but not DAG, is the primary lipolysis-derived
E-MCF in GIIS. The target of MAG appears to be the exocytotic
modulator Munc13-1, since we observed that this DAG receptor
binds MAG more efficiently than DAG (S. Zhao, Y. Mugabo,
J. Iglesias, L. Xie, V. Delghingaro-Augusto, R. Lussier,
M.-L. Peyot, E. Joly, M.A. Davis, J.M. Brown, A. Abousalham,
H. Gaisano, S.R.M.M., andM.P., unpublished data) and because
GIIS is decreased in islets from Munc13-1+/ mice (Kwan et al.,
2006).
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release of appreciable amounts of FFA from b cells (Martins
et al., 2004). FFA can activate the Gq-coupled FFA receptor
GPR40, leading to sn1,2-DAG production and subsequent
activation of downstream targets, including protein kinase C
(Yaney et al., 2002) and protein kinase D (Sumara et al., 2009),
both implicated in glucose- and FFA-stimulated insulin secretion
(Ferdaoussi et al., 2012). One study showed that FFA augments
exocytosis in single patch-clamped b cells and enhances
the size of the readily releasable pool of granules as well as
increases L-type Ca2+ channel activity (Olofsson et al., 2004).
The importance of intracellular FFA and released FFA acting
as autocrine and paracrine signals in GIIS remains to be
determined.
Intracellular FFAs are rapidly activated by long-chain acyl-CoA
synthase (ACSL) to FA-CoAs that have signaling functions. FA-
CoA caused exocytosis in single patch-clamped b cells in one
study (Deeney et al., 2000), but this was not confirmed in another
(Olofsson et al., 2004). FA-CoA modulates signaling effectors in
various cell types and serves as substrate for protein acylation
(Corkey et al., 2000; Resh, 2012). A recent metabolomic flux
study showed that glucose stimulation of INS832/13 cells en-
hances flux into Gro3P and esterification of FA-CoA, resulting
in rapid consumption of FA-CoA and de novo generation of
phosphatidic acid and diacylglycerol (Lorenz et al., 2013).
Glucose stimulation of INS832/13 cells was associated with a
rapid and quantitatively important reduction in the total cellular
content of FA-CoA (Lorenz et al., 2013), as we observed previ-
ously in HIT b cells (Prentki et al., 1992). Because FA-CoA binds
the Kir6.2 subunit of KATP channels (Bra¨nstro¨m et al., 1998) and
potently activates these channels at low micomolar concentra-
tions (Bra¨nstro¨m et al., 1997; Gribble et al., 1998), it was hypoth-
esized that a glucose-induced decrease of FA-CoA, in addition
to increased ATP/ADP ratio, may contribute to KATP channel
closure (Lorenz et al., 2013). Thus, FA-CoA may play a role in
GIIS not only via its use in GL/FFA cycling for the production of
lipid signaling molecules. In addition, their possible reduced
cytosolic concentration at high glucose may contribute to
KATP/Ca
2+ signaling. However, a limit of this novel view for a
role of FA-CoA in GIIS is that its concentration under various
experimental conditions specifically in the cytosolic compart-
ment is unknown.
Emerging Negative and Decelerating Metabolic
Pathways
Most biological processes are regulated by both positive and
negative modulation to ensure their smooth operation. The rela-
tive strength and rapidity in the response of these on and off
signals determines the final output of a given process. Practically
all work aimed at elucidating themetabolic signaling pathways of
FIIS has been focused on activation processes, whereas little
work has been done on the negative metabolic regulation of
insulin secretion. This contrasts with our knowledge of the dual
control of insulin secretion by the autonomic nervous system
via the vagus nerve (stimulatory) and the adrenergic system
(inhibitory). Complementary to the fuel-induced generation of
MCF, mechanisms exist that control the amplitude, duration,
and oscillations in the levels of MCF through negative effectors.
Inhibition of these negative pathways enhances insulin secretion.Fatty Acid Oxidation and CPT-1/Malonyl-CoA Signaling
A well-studied negative modulator of insulin secretion is
mitochondrial CPT-1, which catalyzes the limiting step of
b-oxidation. A highly active CPT-1 channels fatty acids toward
their b-oxidation in mitochondria, thereby diverting FFA away
from the generation of lipid amplification signals of insulin
secretion (Figures 2 and 4). At elevated glucose, malonyl-CoA
is produced in the cytosol, which reversibly inhibits CPT-1 and
thus promotes the formation of amplifying lipid signals.
AMPK
Malonyl-CoA synthesis is accomplished by acetyl-CoA carbox-
ylases 1 and 2, localized in the cytosol and on the mitochondrial
outer membrane, respectively. The activity of both enzymes is
negatively regulated by AMPK under low fuel conditions, and
enhanced at high concentrations of fuel stimuli (Ruderman and
Prentki, 2004). Hence, the availability of malonyl-CoA for the
regulation of CPT-1 is under the negative control of AMPK,
making this enzyme an off modulator of insulin secretion. Thus,
acute activation of AMPK by the insulin sensitizers pioglitazone
andmetformin decreases GIIS (Lamontagne et al., 2009; Leclerc
et al., 2004). In contrast, inhibition of AMPK by compound C
stimulates GIIS (Lamontagne et al., 2009). Although genetic
deletion studies (Beall et al., 2010; Sun et al., 2010) did not
unequivocally identify the catalytic AMPK subunit relevant for
the negative regulation of insulin secretion (Fu et al., 2013; Rutter
and Leclerc, 2009), genetic studies with the upstream activator
LKB1 showed that AMPKa1 is probably playing a negative
modulatory role (Fu et al., 2013). However, the g subunit of
AMPK may also be involved since ATP binding on this subunit
is displaced by both AMP and ADP, leading to AMPK activation
(Xiao et al., 2011). Besides ACC enzymes, there are likely
additional targets implicated in the negative effect of AMPK
activation on FIIS. These may include malonyl-CoA decarboxy-
lase and several enzymes of the GL/FFA cycle (Prentki and
Madiraju, 2008).
a/b-Hydrolase Domain 6
Our recent studies demonstrate that MAG is a signal in the lipid
amplification of GIIS (see above). Since the levels of signaling-
competent MAG are regulated by ABHD6, a plasma mem-
brane-bound MAG hydrolase, we postulate that ABHD6 is a
negative regulator of insulin secretion. Thus, pharmacological
inhibition of ABHD6 in b cells causes enhanced GIIS ac-
companied by elevated MAG levels, and genetic deletion
of ABHD6 has similar effects (S. Zhao, Y. Mugabo, J. Iglesias,
L. Xie, V. Delghingaro-Augusto, R. Lussier, M.-L. Peyot,
E. Joly, M.A. Davis, J.M. Brown, A. Abousalham, H. Gaisano,
S.R.M.M., and M.P., unpublished data).
Short-Chain 3-Hydroxyacyl-CoA Dehydrogenase
Besides CPT-1, an additional b-oxidation enzyme negatively
regulates FIIS. Short-chain 3-hydroxyacyl-CoA dehydrogenase
(HADHSC) catalyzes the NAD+-dependent oxidation of short-
chain 3-hydroxyacyl-CoA to 3-oxoacyl-CoA. This limiting
enzyme of b-oxidation (Bartlett and Eaton, 2004) is very abun-
dant in islets relative to other tissues and relative to other
b-oxidation enzymes in b cells. This is intriguing, particularly in
light of the fact that genetic deficiency of HADHSC causes
hyperinsulinemic nonketotic hypoglycemia (Clayton et al.,
2001; Eaton et al., 2003; Molven et al., 2004). In one study,
knockdown of HADHSC in INS-1 cells andmouse islets elevatedCell Metabolism 18, August 6, 2013 ª2013 Elsevier Inc. 175
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2007). In another study, HADHSC knockdown increased insulin
secretion at both low and high glucose in INS cells and rat b cells,
surprisingly without altering the oxidation of long-chain fatty
acids (Martens et al., 2007). We showed that HADHSC knock-
down increased both fuel- (glucose or glutamine plus leucine)
and non-fuel-induced secretion (e.g., high KCl) in INS cells; this
probably involves transaminase activity and the formation of
short-chain acyl-carnitine compounds (Pepin et al., 2010).
HADHSC KO mice are hypersensitive to an oral amino acid
load, which causes an abnormally elevated insulin secretion
response to amino acids (glutamine plus leucine) both in vivo
and ex vivo (Li et al., 2010). Enhanced oxidative deamination
activity of GDH (in the anaplerotic direction) is likely instrumental
in the mechanism whereby inactivating mutations of HADHSC
cause hyperinsulinemia (Pepin et al., 2010). This view is sup-
ported by the observation that GDH and HADHSC interact
physically (Li et al., 2010). Thus, HADHSC negatively modulates
insulin secretion in response to amino acids, and perhaps to
glucose as well, via its activity and/or protein/protein interaction
(HADHSC/GDH).
Cytosolic Isocitrate Dehydrogenase
Cytosolic isocitrate dehydrogenase 1 (IDH1) may participate in
pyruvate cycling processes linked to GIIS. One study reported
that IDH1 knockdown in INS832/13 cells and rat islets reduces
the NADPH/NADP ratio and GIIS (Ronnebaum et al., 2006); how-
ever, the same authors in a later work suggested that the
NADPH/NADP ratio may not be a major player in GIIS (Odegaard
et al., 2010). Because of this uncertainty, we reexamined the role
of IDH1 in GIIS using INS832/13 cells and rat islets. To our sur-
prise, we found that IDH1 knockdown results in enhanced GIIS
(C. Guay, E´. Joly, E´. Pepin, A. Barbeau, L. Henstch, M. Pineda,
S.R.M.M., H. Brunengraber, and M.P., unpublished data), sug-
gesting to us that IDH1 negatively controls GIIS. The mechanism
implicates an elevation in Krebs cycle intermediates, ATP and
cAMP at high glucose, and enhanced pyruvate/citrate cycling.
In support of the view that flux through IDH1 causes deceleration
of GIIS, IDH1 activity is elevated in islets from type 2 diabetic
patients that are less glucose responsive (MacDonald et al.,
2009b). Flux through IDH1 in the isocitrate-to-a-ketoglutarate
direction may reduce GIIS by diverting cataplerotic carbons
(isocitrate) from pyruvate/citrate cycling, curbing this cycle,
which may be important for secretion. Another possibility is
that reverse flux through cytosolic IDH1 (a-ketoglutarate to
isocitrate) negatively regulates GIIS by (1) consuming the
coupling factor NADPH and (2) removing a-ketoglutarate, a
cofactor of prolyl hydroxylase, which hydroxylates and flags
hypoxia-inducible factor-1a (HIF-1a) for degradation, leading
to the stabilization of HIF1a, a negative modulator of insulin
secretion (Cantley et al., 2010). The role of IDH1 in GIIS is un-
settled and merits further investigation.
Uncoupling Protein 2
Although initial studies suggested that uncoupling protein 2
(UCP2) acts as an uncoupling protein in the b cell linked to the
control of ATP production, recent studies (Brand et al., 2010)
indicate that this possibility is likely erroneous, as it was based
on UCP2 KOmodels with mixed genetic backgrounds that intro-
duced artifacts and on studies in which UCP2 was expressed at
very high toxic levels. Although the function of UCP2 in various176 Cell Metabolism 18, August 6, 2013 ª2013 Elsevier Inc.biological processes is debated, there is strong evidence that,
unlike UCP1, it is not a physiologically relevant uncoupling
protein. The balance now supports the view that amajor function
of UCP2 is to attenuate the mitochondrial production of ROS. A
consequence of its ROS-scavenging ability is that UCP2 could
act as a negative modulator of FIIS not primarily via reducing
ATP production, but by reducing ROS (Brand et al., 2010;
Robson-Doucette et al., 2011) that may act as E-MCF for insulin
secretion. Consistent with this view, overexpression of UCP2 at
nontoxic levels did not alter mitochondrial metabolism and ATP
production in INS cells, whereas overexpression of UCP1 did
(Galetti et al., 2009). UCP2 is activated by ROS themselves,
which are elevated in the b cell at high concentrations of fuel
stimuli. Thus, UCP2 acts as a safeguard for excessive toxic
ROS production. It may also prevent exaggerated insulin secre-
tion by reducing ROS levels and by reducing ATP production if it
has mild uncoupling activity. One study reported a congenital
hyperinsulinism linked to a UCP2 coding variant (Marquard
et al., 2011). This is compatible with a role of UCP2 in regulating
both ATP and ROS acting as MCFs.
Glucose-6-Phosphatase, Catalytic, 2
Genome-wide association studies indicated that SNPs within
the human glucose-6-phosphatase, catalytic, 2 (G6PC2)
gene are associated with variations in fasting blood glucose
(Bouatia-Naji et al., 2008). G6PC2, formerly known as islet-
specific glucose-6-phosphatase catalytic subunit-related pro-
tein (IGRP), is primarily expressed in islet b cells. The enzyme
catalyzes the hydrolysis of glucose-6-phosphate to glucose
and inorganic phosphate within the endoplasmic reticulum
(ER). Human genetic data are consistent with the observation
that G6PC2 KO mice show a slight reduction in fasting blood
glucose (Wang et al., 2007). A study in G6PC2 KOmice indicated
that G6PC2 is a negative regulator of basal GIIS by opposing the
action of glucokinase (Pound et al., 2013). Perfused pancreases
and isolated islet studies in G6PC2 KO mice showed a leftward
shift in the dose-response curve of GIIS (Pound et al., 2013), and
basal cytoplasmic calcium levels were elevated in G6PC2
KO islets. Thus, a glucokinase/glucose-6-phosphatase futile
substrate cycle exists in b cells and may be relevant to reduce
glycolytic flux and insulin secretion under physiological condi-
tions such as during exercise, hyperinsulinemia, or diabetes.
Islet glucose-6-phosphatase activity is elevated in various
models of type 2 diabetes, particularly in Goto-Kakizaki (GK)
(Ling et al., 2001), Zucker diabetic fatty (ZDF) (Tokuyama et al.,
1995), 90% partial pancreatectomized (Laybutt et al., 2002),
and neonatal streptozotocin-induced diabetic (Khan et al.,
1990) rats. Enhanced glucose/glucose-6-phosphate cycling
may contribute to the altered GIIS in diabetes but may also be
an adaptive mechanism to prevent b cell exhaustion and death.
In sum, we are beginning to define the pathways and enzymes
implicated in reducing FIIS (Figure 1). Hyperinsulinemia-induced
hypoglycemia is a much worse enemy for the organism than
hyperglycemia due to sluggish GIIS because it may be fatal.
Thus, the body must have means to prevent insulin-induced
hypoglycemia via a number of decelerating metabolic signaling
pathways that we are beginning to understand. One such decel-
erating metabolic signaling pathway is enhanced fat oxida-
tion and the malonyl-CoA/AMPK/peroxisome proliferator-
activated receptor a (PPARa)/PPARd network that regulates lipid
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cell fat oxidation, by removing lipid signaling molecules from
the GL/FFA cycle, prevents exaggerated insulin secretion and
hypoglycemia during fasting when FFA are elevated (Prentki
and Madiraju, 2012).
Facts and Artifacts of In Vitro Veritas
The islet b cell metabolic signaling literature is often perplexing.
It is hard to find a single candidate MCF where the jury is un-
equivocal; approximately one third of papers advocate either a
definitive yes, no, or maybe. Debates have dragged on for
decades with no resolution. We suggest that there are good
reasons that have led to this situation.
Part of the explanation lays in the greatly different experi-
mental conditions used, highly important among them the choice
of basal fuel levels in islets during preincubations and incuba-
tions ex vivo. Some investigators use zero glucose with no other
fuel added, others 2.8 mM glucose, others a basal concentration
of glucose (1–5mM) plus 1–2mMglutamine, etc. Fatty acids and
some amino acids that are major nutrients in the blood are rarely
present in incubation media. Thus, fuel depletion under basal
conditions often compromises these studies, and comparison
to what happens in a stimulatory condition can be misleading.
One should remember that the glucose S0.5 of glucokinase is
about 8 mM, while the concentration dependency is sigmoidal.
Consequently, at 1–3 mM glucose, glycolytic flux is very low
and variable because b cells barely express high-affinity hexoki-
nases. Because endogenous glycogen and triglyceride stores
are limited in b cells, in the absence of additional exogenous
fuels, islet b cells incubated in vitro under these conditions are
fuel deprived. So-called basal conditions of islet incubations
are typically associated with metabolic stress (fuel scarcity),
to which a single very high glucose concentration (e.g.,
16–30 mM glucose) or an unphysiological fuel combination
(e.g., 10 mM glutamine plus 10 mM leucine) are compared,
causing a metabolic stress in the opposite direction (fuel
excess). Since metabolic stress is associated with drastic
changes, such as high ROS production, many responses and
phenomena observed upon refueling probably have little to do
with specific signaling events of stimulus-secretion coupling
but are all too often interpreted as if they were.
We reviewed above why studying lipid signaling in GIIS in the
absence of exogenous FFA may lead to striking results and why
these may have little relevance for normal physiology. Similarly,
studying pathways of GIIS linked to amino acid metabolism in
the absence of exogenous amino acids, such as alanine, gluta-
mine, and leucine, may also lead to incorrect conclusions.
Finally, exploring metabolic signaling under only basal (low
glucose) and maximal (high glucose) conditions is far from an
ideal design. Physiological intermediate glucose concentra-
tions should be included to define correlations for a full dose
dependency and to identify overriding effects that might occur
at very high glucose concentrations in metabolic enzyme knock-
down experiments. Also, total KO or overwhelming reduction of
a metabolic step by RNAi may produce results that are easily
misinterpreted.
A closely related aspect is the almost total neglect of the
principle of control strength, which is essential to identification
of limiting steps in metabolic control and signaling (Westerhoff,2008). For example, effects of a total KO of a particular meta-
bolic reaction are frequently overinterpreted or misintrepreted
since such a manipulation fully blocks an entire pathway, with
many consequences downstream. Also, this approach does
not provide information about the control strength of a specific
process within a signaling pathway or whether it is high (1 or
close to 1) or low (e.g., 0.1). Only graded reduction or enhance-
ment of the process in question will provide this critical informa-
tion. Thus, a functional relevance of a given process can be
judged from the impact of the graded manipulation on the
relative rates of a participating step (e.g., phosphofructokinase)
and its related pathway (e.g., glycolysis) and process (e.g.,
insulin secretion).
Pathways of FIIS identified ex vivo (using isolated islets) or
in vitro (using b cell lines) that are established in minimal media
may not necessarily translate correctly to the in vivo situation.
One recent study compared GIIS and INS832/13 metabolism
in Krebs-Ringer bicarbonate (KRB) medium versus Dulbecco’s
modified Eagle’s medium (DMEM). O2 consumption rate corre-
lated well with FIIS in KRB medium, but not in DMEM (Cline
et al., 2011). Hence, we propose that the coupling mechanism
implicated in islet b cell metabolic signaling should be studied
in the future usingmore physiological KRBmedium that includes
basal glucose at 4–5 mM, together with amino acids, e.g., non-
stimulatory concentrations of glutamine (1–2 mM) or a complete
physiological amino acid mixture (4 mM), and FFAs, e.g., 1:1
oleate and palmitate mixture not exceeding 0.2 mM, bound to
0.5%–1% albumin.
Is there an Ideal Model for Fuel Signaling?
Several biological systems have been used to study the coupling
mechanisms of FIIS. These include the intact organism, the
isolated perfused pancreas, pancreas slices, isolated mouse,
rat, and human islets, cell-sorted b cells, microdissected islets
from freeze-dried frozen pancreases, and a number of tumoral
b cell lines. Pancreatic slices were abandonedwhen collagenase
isolation of islets became available in the 1960s, and microdis-
sected islets have been used in a very limited number of studies
(Ghosh et al., 1991; Matschinsky et al., 1986a). Cell lines have
provided very useful information, particularly the more recent
lines (INS-1, INS-1E, INS832/13, andMIN-6) derived from rodent
tumors. A human cell line has recently been described (Ravas-
sard et al., 2011), but its availability and usefulness for metabolic
signaling studies remains to be proven.
Tumor-derived cell lines present the advantages that they
consist of a homogeneous population of b cell-like cells in
good metabolic condition and tissue availability is not limited.
Nevertheless, metabolism is altered in tumoral cells since cancer
cells are transformed and tuned for proliferation.
Freshly isolated or cultured rodent islets are widely used since
they represent a more physiological model. However, an impor-
tant concern with isolated islets is that metabolic signaling of b
cells is different from non-b cells (Schuit et al., 1997), which
contribute to approximately 40% of the islet mass. There is
also the danger of contaminating exocrine tissue and of signifi-
cant central islet necrosis after organ culture, particularly in large
islets, where O2 and nutrient diffusion to the center of the islet is
limiting in middle size and large islets. In addition, rodent islets
from different species are not equal. For example the anapleroticCell Metabolism 18, August 6, 2013 ª2013 Elsevier Inc. 177
Figure 5. Integrated View of Metabolic Signaling Pathways Generating Metabolic Coupling Factors for Insulin Secretion
The metabolic coupling factors affecting insulin secretion are shown in blue. The metabolic pathways, including the GL/FFA cycle, Krebs cycle, and pyruvate
cycles, are discussed in Figures 2, 3, and 4. ATP closure of K+ATP channels depolarizes the plasma membrane and opens voltage-dependent Ca2+ channels
(VDCC). The resulting Ca2+ influx is needed for insulin granule fusion with the plasma membrane. Intracellular Ca2+ levels also increase by release from the ER
stores, triggered by inositol triphosphate (IP3), which is produced during FFA signaling via GPR40, during stimulation of acetylcholine receptor (AChR) signaling
and via Ca2+ activation of phospholipase C enzymes following the opening of VDCC (not shown). GPR40 and AChR (both Gq-associated G protein-coupled
receptors) signaling also produces 1,2-DAG, which activates PKC and PKD enzymes that are involved in insulin secretion. Signaling via the glucagon-like peptide
1 (GLP1) receptor andGPR119, and by glucose stimulation, results in cAMP production fromATP. cAMP activates exchange protein directly activated by cAMP 2
(Epac2) and protein kinase A (PKA), both of which promote exocytosis. Negative modulation of insulin secretion is exerted by the activation of GPCRs,
a-adrenergic receptor (aAdrR), somatostatin receptor (SstR), and galanine receptor (GalR). Acyl-CoAs, including acetyl-CoA, malonyl-CoA, and FA-CoA, may
also be used for protein acylation, which can impact insulin granule exocytosis. Kir6.2, inwardly rectifying KATP channel subunit; SUR1, regulatory subunit of the
K+ATP channel and the target of sulfonylureas; b-ox, b-oxydation; CPT-1, carnitine plamitoyltransferase 1; PIP2, phosphatidylinositol 4,5-bisphosphate. Other
abbreviations are given in Figures 2, 3, and 4.
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Reviewsecretagogue methyl succinate is very efficient in rat islets, but
not in mouse islets (MacDonald, 2002), and second-phase GIIS
is prominent in rat islets compared tomouse islets. Malic enzyme
is abundant in rat and human islets but poorly expressed in
mouse islets (Heart et al., 2009; MacDonald, 2002).
There are also subtle differences between rodent and human
islets. The central role of the glucose transporter GLUT2 in
rodent b cells is established, but a number of studies have shown
that GLUT1 and GLUT3 play an important role in facilitating
glucose transport into human b cells (Schuit, 1997). Human islets
appear to depend less on pyruvate carboxylation than rodent
models for GIIS (MacDonald et al., 2011). Overall though, the
characteristics of GIIS in human islets are similar to those of
rodent islets (Henquin et al., 2006a). The pattern of the biphasic
response to glucose is superimposable to that of mouse islets,
but the concentration-response curve is shifted to the left (Doliba
et al., 2012; Henquin et al., 2006a), reflecting the slightly lower178 Cell Metabolism 18, August 6, 2013 ª2013 Elsevier Inc.basal glycemia in human versus rodents. Nonetheless, human
islets cannot be obtained easily, and their characteristics vary
much with the donor and quality of the isolation.
Some investigators have studied glucose signaling in suspen-
sions of purified rodent b cells (Detimary et al., 1998; Sekine
et al., 1994). This approach was essential to show that normal
b cells contain a very small amount of lactate dehydrogenase
and that rat b cells metabolize glucose essentially via aerobic
glycolysis, whereas glycolysis in non-b cells is largely anaerobic
(Schuit et al., 1997; Sekine et al., 1994). Glucose causes a rise in
the ATP/ADP ratio in b cells, but not in a cells (Detimary et al.,
1998). If isolated b cells are a suitable model for addressing
certain questions, there are certainly some disadvantages. The
approach provides very little biological material and does not
allow intercellular communication between b cells themeselves
or between b cells and non-b cells that play an important regula-
tory role in GIIS (Serre-Beinier et al., 2002).
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ReviewThus, there is not a single ideal model to study fuel signaling in
the b cell, and all listed models, including the more recent
tumoral b cells, are useful tools for studying this process. How-
ever, whenever possible, key data obtained in cell lines should
be confirmed in normal islet tissue.
Concluding Remarks
Despite decade-long efforts by many laboratories and the appli-
cation of powerful new approaches, our understanding of the
mechanisms involved in FIIS remains limited. This lack of clear
understanding may be the consequence of the enormous
complexity of metabolism-based signaling processes still
beyond the reach of current technology, and perhaps also
because our conceptualization of the problem is still inadequate.
Nature’s stunning ability to build redundancy into homeostatic
systems essential for life and the existence of multiple levels of
regulation needed for precise control of insulin release un-
doubtedly contribute greatly to the difficulties of the tasks facing
the investigator.
Only a few of the large list of candidate MCFs thought to be
critical in fuel-based stimulus-secretion coupling (Figure 5) pre-
sented in this article have been linked convincingly to an effector
system. The search could perhaps be more successful if it were
focused on late effectors in the process, e.g., the exocytotic ma-
chinery, cytoskeletal proteins, and plasma membrane channels.
We should consider not only on signaling for secretion, but also
offmechanisms. Given such reorientation, we anticipate that the
next decade will result in solid new insights, most certainly aided
by the application of new metabolomics and systems biology
tools that have just begun to transform this area.
The knowledge that will be gained in b cell metabolic signaling
will have significant implications for our understanding of fuel-
sensing processes in other organs, such as specialized cells in
the pituitary, brain, and gut, that are even less easily accessible
to experimentation. Finally, the identification of the pathways
and coupling factors that are late in the metabolic signaling pro-
cesswill help us to understand thebiochemical basis of isletb cell
failure in diabetes and design new classes of antidiabetic drugs.
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